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SUMMARY 
Genome-wide expression and methylation studies in patients with pancreatic 
adenocarcinoma (PDAC) indicate that numerous genes involved in the development 
of cancer are highly methylated in their promoter regions but are nevertheless strongly 
transcribed. The mechanisms underlying the relationship between altered DNA 
methylation and increased transcription, as well as the effects on cancer development 
remain elusive. 
 
Recent systematic investigations have shown that many transcription factors (TFs) 
which lack methyl-CpG binding domains (MBDs) can also bind to methylated DNA in 
vitro and in vivo. As a consequence, the binding preference of such TFs to mCpG 
leads to the activation of gene expression, the splicing regulation, and the chromatin 
remodeling. Based on these observations, it’s hypothesized that TFs that specifically 
bind to highly methylated promoters are involved in the regulation of transcription 
activity. 
 
With the help of protein microarrays covering 667 DNA binding domains of TFs, the 
binding patterns of the methylated/unmethylated promoter together with TFs were 
analysed after incubating the promoter on the TF-microarray. The analysis results 
showed that the transcription factors NFATc1/2/3 (Nuclear Factor of Activated T cells 
1/2/3) of the NFAT family preferentially bound to the methylated promoters. Afterward, 
NFATc1 was selected for further investigation since it was upregulated in PDAC 
tissues compared with healthy tissues. The viability, colony, and migration assays 
indicated that NFATc1 played an oncogenic role in pancreatic cancer cell lines (Panc1 
and Miapaca2). To better understand how NFATc1 regulates transcription, mRNA 
profiling of NFATc1-knockdown cells was used to determine the down-regulated 
genes. The decreased expression of ALDH1A3 was confirmed further by q-PCR. Next, 
in silico analysis revealed that multiple methylated/unmethylated binding sites of 
NFATc1 were in the promoter region of ALDH1A3. In addition, luciferase assay and 
chromatin immunoprecipitation (ChIP) verified that NFATc1 directly regulated the 
transcription of ALDH1A3. Moreover, the in vitro methylation and the ex vivo 
demethylation assay also showed that NFATc1 regulated the transcription of 
ALDH1A3, though the promoter region was methylated.  
 
In summary, this work reveals that NFATc1 plays an oncogenic role in pancreatic 
cancer cell lines (Panc1 and Miapaca2) and regulates the transcription of ALDH1A3, 
though DNA methylation is in its promoter region. The elucidation of the methylation-
dependent binding of NFATc1 provides insights for a better understanding of 
methylation-mediated biological processes. 
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ZUSAMMENFASSUNG 
Genomweite Expressions- und Methylierungsstudien an Patienten mit Pankreas-
adenokarzinom (PDAC) deuten darauf hin, dass zahlreiche an der Krebsentstehung 
beteiligte Gene in ihren Promotorregionen zwar hochgradig methyliert sind aber 
dennoch stark transkribiert werden. Die Mechanismen, die der Beziehung zwischen 
veränderter DNA-Methylierung und erhöhter Transkriptionsrate zugrunde liegen sowie 
die Auswirkungen auf die Krebsentwicklung sind weitgehend unverstanden. 
 
Neuere systematische Untersuchungen haben ergeben, dass viele Transkriptions-
faktoren auch ohne Methyl-CpG-Bindungsdomäne (MBD) in vitro und in vivo an 
methylierte DNA binden können. Die bevorzugte Bindung an mCpG führt dann zur 
Aktivierung der Genexpression, der Spleißregulation und zum Umbau des Chromatins. 
Aufgrund dieser Beobachtungen gehen wir davon aus, dass Transkriptionsfaktoren, 
die spezifisch an hochmethylierte Promotoren binden, an der Regulation der 
transkriptionellen Aktivität beteiligt sind. 
 
Mit Hilfe von Protein-Microarrays, die 667 unterschiedliche DNA-Bindungsdomänen 
von Transkriptionsfaktoren repräsentieren, wurde das Bindungsverhalten an 
methylierte und nicht methylierte Promotorregionen untersucht. Nach Inkubation der 
Arrays mit den entsprechenden DNA-Fragmenten zeigte sich, dass die 
Transkriptionsfaktoren NFATc1/2/3 (Nukleärer Faktor von Aktivierten T-Zellen 1/2/3) 
der NFAT-Familie vorzugsweise an methylierte Promotoren binden. Da NFATc1 in 
PDAC-Geweben im Vergleich zu gesundem Gewebe hochreguliert wird, wurde 
NFATc1 für die weiteren Untersuchungen ausgewählt. Der Lebensfähigkeit, der 
Kolonieassay sowie der Migrationstest zeigten, dass NFATc1 eine onkogene Rolle in 
den PDAC-Zelllinien Panc1 und Miapaca2 spielt. Um genauer zu verstehen, wie 
NFATc1 die Transkription reguliert, wurde durch mRNA-Profiling von NFATc1-siRNA-
Knockdown-Zellen untersucht, welche Gene herunterreguliert wurden. Die 
verminderte Expression des dabei entdeckten ALDH1A3 wurde durch q-PCR bestätigt. 
Zudem ergab eine Sequenzanalyse, dass die Promotorregion von ALDH1A3 
mehrfach methylierte/ nicht methylierte Bindungsstellen für NFATc1 aufweist. Durch 
LuziferaseAssay und Chromatin-Immunpräzipitation (ChIP) konnte die 
transkriptionelle Regulation durch NFATc1 weiter bestätigt werden. Schließlich zeigte 
der In-vitro-Methylierungs- und der Ex-vivo-Demethylierungsassay, NFATc1 die 
Transkription von ALDH1A3 regulierte, obwohl die Promotorregion methyliert war.  
 
Zusammenfassend lässt sich aufgrund der vorgestellten Ergebnisse sagen, dass 
NFATc1 eine onkogene Rolle in Pankreaskrebszelllinien (Panc1 und Miapaca2) spielt 
und die Transkription von ALDH1A3 reguliert, obwohl sich die DNA-Methylierung in 
seiner Promotorregion befindet. Die Aufklärung der methylierungs-abhängigen 
Bindung von NFATc1 liefert weitere Erkenntnisse zum besseren Verständnis 
methylierungsvermittelter biologischer Prozesse. 
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1 Introduction 
1.1. What is gene transcription? 
1.1.1. The general process of gene transcription 
Transcription is the starting point of DNA-based gene expression, in which a segment 
of DNA is copied into RNA molecule by RNA polymerase [1]. In the process of 
transcription, RNA polymerase in cooperation with general transcription factor binds 
to core promoter DNA and initiates the transcription. Specific transcription factors 
control the rate of transcription and thus make sure genes are expressed at right place, 
at right time, and in the right amount by recognizing multiple cis-acting regulatory 
elements including promoters, enhancer, silencers and insulator/boundary elements 
[2] in a sequence-specific manner. In general, the process of transcription can be 
divided into initiation, promoter escape, elongation and termination, and DNA stores 
all the code of controlling the transcription.  
 
Gene transcription is the result of complexed process especially in eukaryotic 
organisms. As for prokaryotes, genes are organized into operons and transcribed into 
RNA with the modulation of a single promoter. However, eukaryotic organisms utilize 
much more complex mechanisms to regulate expression. Firstly, apart from the 
protein coding genome, around 99% genome context is non-coding part. Recent 
Encyclopedia of DNA Elements (ENCODE) project have revealed that a big fraction 
of non-coding genome are cis-regulatory elements. Promoters, enhancers, silencers 
and insulators could fine-tune the gene expression in a cell-type specific and/or 
biological context dependent manner [3]. Secondly, apart from the genomic aspects, 
the gene expression can also be modulated by the chromosome structure, and the 
factor of inter-chromosomal interactions comes to researchers’ attention. Thirdly, the 
cooperativity of TFs and interactions with nucleosomes and/or TF co-factor also have 
effects on the transcription regulation. Additionally, epigenetic modification, including 
histone modification also contributes to the regulation of transcription [4]. These are 
Introduction 
 7 
 
illustrated in the figure below. However, the complexity of transcription regulation is 
still remaining elusive.  
 
Figure 1.1 The simplified model of transcription initiation. 
The simplified model of transcription initiation, figure is modified from [5]. a, transcription starts with TFs 
binding in the cis-regulatory element’s region. b, TFs then recruit other co-activation including chromatin 
remodelers or modifiers to alter the structure of the chromatin and make it more accessible to the other 
factors. c, preinitiation complex (PIC) is formed in the core promoter region. PIC includes includes Pol 
II (12 subunits) and general transcription factors. d, phosphorylated Pol II escapes from the promoter 
and the elongation step starts. 
 
1.1.2. The transcription cis-regulatory element 
Coding genes are roughly distributed in 1% genome region. The function of the vast 
majority of the human genome still remains unclear. ENCODE project, started in 2003, 
has performed diverse sequencing-based methods to decode the human genome 
especially the non-coding sequence.  Inspiringly, they have identified that over 80% 
genome participate in transcription-associated biochemical events in the cell line 
they’ve studied [6]. Non-coding DNA sequences that are located in or near one coding-
gene region and required for proper spatiotemporal expression through binding TFs, 
are called cis-regulatory sequences [7]. As cis-regulatory elements store the 
information to control when, where and how the gene is expressed, the functional 
characterization of cis-regulatory elements including promoter, enhancer, insulator, 
silencer and super enhancer is essential to better understand how genes transcription 
is regulated [8].  
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In eukaryotic genome, three classes of promoters have been identified based on 
relative distance to the transcription starting sites (TSS): the core promoter, the 
proximal promoter and the distal promoter. The core promoter contains TSS, RNA 
polymerase binding site, general TF binding sites, and spaces between them, which 
is the essential component for transcription initiation, but not sufficient to mediate the 
efficient transcription by itself [9]. To achieve efficient transcription, proximal and distal 
promoters which contain a cluster of sequence-specific TF binding sites are required. 
The proximal promoter is normally located around 250bp upstream of TSS and the 
distal promoter resides further upstream in the same strand as TSS. The activity of 
these elements depends on the relative location and orientation [2]. 
 
Another type of regulatory elements containing multiple specific TF binding sites to 
greatly increase transcription rates are called enhancers. Enhancers are normally 
accommodated several kilobases or even hundreds of kilobases (kb) upstream or 
downstream of the target gene. At a distance, the enhancers regulate the transcription 
in a DNA-looping model, that a DNA loop brings activator proteins bound to distant 
enhancer elements into protein complexes which are associated with promoter-
proximal cis-acting sequences [10]. In human genome, there are approximately 1 
million enhancers that activate transcription in a tissue-specific manner, which can be 
explained by two hypotheses: one is that certain activator proteins are dominantly or 
exclusively expressed in specific cell types; the other explanation is that tissue-specific 
repressor-silencer complex is formed to block binding of TFs into the enhancer region 
[11]. 
 
Other regulatory elements include insulator, silencer, and super enhancer. Insulator, 
also name boundary element, is a class of regulatory element containing clustered 
binding sites for sequence-specific DNA binding proteins which mediate intra and 
inter-chromosomal interactions. As an inter-chromosomal interaction mediation, it 
blocks the cross talk between enhancers and promoter of the neighboring genes. On 
the other hand, it acts as a barrier to protect the active gene from the heterochromatin 
[12]. In contrary to the enhancers, silencers prevent genes from being expressed and 
are categorized into two classes: For classical silencers, the gene is actively repressed 
when the silencers interfere binding with general transcription factor (GTF) binding. 
For non-classical silencers, the mechanism is rather complex through which gene 
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expressions are repressed by silencers in a way of recruiting the transcription 
repressor to disrupt the transcription process [13]. Super enhancers are newly 
identified regulatory elements that control the expression of crucial genes which can 
determine the cell entity and cell state. Super enhancers are a cluster of enhancers 
and densely bound by the high levels of transcription factors and mediators. As a result, 
the transcription is enhanced with abundant transcripts of target genes. Furthermore, 
expression of genes associated with super-enhancers is particularly sensitive to 
perturbations, which may facilitate cell state transitions. Indeed, this has been 
confirmed indeed in the case of cancer. Super enhancers are bound by a cluster of 
key oncogenes or transcription factors which can determine the tumor cell phenotype 
[14]. The disease-associated DNA variants are highly enriched in the super enhancers 
of the disease relevant cells. Thus, the information of super enhancers can provide 
biomarkers for therapeutic targets [15].  
 
1.2 What are the transcription factors (TFs)? 
1.2.1 The overview of TFs 
In human genome, with the updated knowledge, around 1639 known transcription 
factors have been identified [16]. Transcription factors are multi-domain proteins 
capable of binding DNA in a sequence-specific manner and regulating transcription 
[17] [18]. DNA binding domains (DBDs) of TFs mainly exert the function of DNA 
binding [19]. Additionally, most human TFs also contain additional protein domains 
including Trans-Activating Domain (TAD) which can interact with other proteins or 
protein complex [20], and Signal Sensing Domain (SSD) which senses external signal 
and in turn regulates the gene expression activity [20]. It is summarized that 78 TFs 
contain multiple homotypic or heterotypic DBDs, 713 TFs contain C2H2 zinc finger 
arrays, and 779 TFs contain only a single DBD .  Based on the types of DNA binding 
domains, TFs are categorized into different families. In a numbering order, the top TF 
family are listed as below: C2H2-ZFs (747 TFs), Homeodomains (196 TFs), bHLH 
(108 TFs), bZIP (54 TFs), Forkhead (49 TFs), nuclear hormone receptor (46 TFs), 
HMG/Sox (30 TFs), and ETS (27 TFs). Additionally, 69 of TFs in this updated list are 
grouped as ‘‘unknown family’’ due to the lack of a canonical DBD [16]. Functionally, 
TF can be classified into 2 classes: The General Transcription Factors (GTFs) and the 
sequence specific transcription factors. Principally, GTFs mainly bind to the core 
Introduction 
 10 
 
promoter region and recruit RNA polymerase II to initiate the transcription. They 
include transcription factor II A/B/D/E/F/H (TFII A/B/D/E/F/H) [20]. Additionally, the 
sequence specific TFs which mainly regulate the rate of transcription and are 
expressed spatially and temporarily.  
 
1.2.2 The motifs of TFs 
TFs play a key role in the recognition regulatory DNA, and binding motif of around 
three-quarters (1211) of human TFs have been identified [16]. Notably, The C2H2-ZF 
family is the biggest TF family, while hundreds of motifs are still not characterized yet. 
Additionally, more efforts are needed to identify binding motifs in multiple TFs families, 
including AT-hook proteins, THAP finger, BED-ZF, and those with unknown DBD [16]. 
In the case of C2H2-ZF family, it’s not available to perform in vitro expression 
concerning large family number, and the proteins of C2H2-ZF family are relatively big 
and thus difficult for the in vitro expression [21]. In summary, within various TFs 
families, same or similar binding motifs are shared by many TFs and this leads to over 
500 specific motif groups [17]. Furthermore, the epigenetic modification of DNA can 
also result in the alteration of TF binding behavior. As an example, DNA methylation 
is a regulator of gene expression [22]. The effect of DNA methylation has been 
analyzed on the binding of 542 human TFs by using methyl-SELEX. In addition to the 
inhibition-binding of some TFs, the mCpGs can also promote binding capacities in 
certain TF families, including Homeobox, POU, and NFAT families [23].  
 
Many models have been developed to describe TF-DNA interaction such as 
degenerate code (IUPAC code) [24], Position Weight Matrix (PWM) model [25], 
binding energy model [26], transcription factor flexible model [26] and connecting 
matrix model [27]. Different models show different emphasis on the coverage of TF-
DNA binding information. IUPAC code is the simplest model but only describes the 
consensus sequence to one TF prefers to bind. However, the affinity of the binding 
site is also needed to be considered. PWM model is introduced to cover this 
information based on the assumption that each position to TF binding is independent. 
While dinucleotide interdependency, dimer formation and other factors are also 
important to the TF binding. Thus, binding energy model, transcription factor flexible 
model and connecting matrix model are established. In general, degenerate code and 
PWM model are used in most cases. These two models are illustrated below. 
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The degenerate code is commonly used and easy to be understood. As TFs can bear 
variance of DNA sequence at each position, degenerate code is used to represent this 
variance. The detailed information is shown in the table.            
      
Table 1.1 IUPAC code for nucleotide 
Code letter Bases covered 
A A 
T T 
C C 
G G 
R A, G 
Y C, T 
W A, T 
S C, G 
M A, C 
K G, T 
B C, G, T 
D A, G, T 
H A, C, T 
V A, C, G 
N A, C, G, T 
 
The PWM model is used to describe the consensus sequence and the affinity 
information collectively. In order to achieve this, a numeric score is assigned. The 
PWM shows the consensus sequence with the highest score at each position. The 
score at each nucleotide position is the ratio of the counts of such nucleotide divided 
by the total counts of all nucleotides. The score for a given DNA consensus sequence 
is the sum of the scores of all positions for such sequence. As an example, the PWM 
model for GBX2 is listed below, the consensus sequence of GBX2 is CCAATTAG [23]. 
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Table 1.2 PWM model for GBX2 
A 1296 48 7783 7783 0 0 7783 1882 
C 2749 4441 409 0 0 152 0 1608 
G 2195 0 201 0 0 97 0 2795 
T 1544 3343 0 0 7783 7783 0 1500 
 
To understand this PWM model, as an example, the score for A at the third position is 
7783 / (7783+409+201+0) = 0.93. The score for a random sequence is 0.25, and any 
nucleotide with the score higher than 0.25 has higher affinity than random. The score 
for the consensus sequence with the sum of highest score at each nucleotide position 
is (0.35+0.57+0.93+1+1+0.97+1+0.36=6.18), and the score for a random sequence of 
8 bases is 0.25*8=2. Any sequence with the score higher than 2 is considered as a 
binding possibility.  
 
1.2.3 The binding physiology of TFs 
TFs bind to DNA in a sequence-specific manner. In terms of protein-DNA interaction, 
it is either direct or indirect contact. Directly, the amino acids of TFs’ side chain interact 
with the binding sites by hydrogen bond or Van Der Waals forces, and thus allows the 
discrimination of sequence [28]. The decoding of 120 crystal structures of DNA-protein 
complexes indicates the hydrogen bonds formed between arginine and guanosine 
nucleotide and between asparagine glutamine and adenosine nucleotide are more 
common than the other pairs [29]. Indirectly, TFs bind with the backbone of standard 
B-form DNA, either with a broader or narrower major groove or being bent. These 
interactions are also sequence associated [30]. In terms of protein-methylated DNA 
interaction, the structure analysis of multiple TFs which show the preference for methyl 
cytosine indicates that the interaction is based on hydrophobic bonds with its 5-methyl 
group [23]. TF-DNA interactions are not extremely strict on the sequence-specificity. 
Thus, TFs could bind with a number of closely related DNA motifs, but with differential 
affinities showing higher specificity than random.  
 
1.2.4 The function of human TFs in genetics and disease 
TFs play central roles in biology. They are responsible for decoding the human 
genome, exerting the function of controlling the gene expression and thus controlling 
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processes that specify cell types and phenotypes [31].  In the case of cancer, diverse 
carcinogenesis events are controlled by TFs. As an example, EMT pathway is mainly 
controlled by a panel of transcription factors including members of the SNAIL, TWIST 
and ZEB (zinc finger E-box-binding homeobox) families [32]. Furthermore, the variants 
of DBDs can alter the sequence specificity. For example, the multiple variants of TP53 
protein lead to the alteration of protein’s activity by changing the protein interactions, 
reviewed in [33].  Moreover, the variants within a regulatory region control the 
expression of a TF and ultimately lead to the altered TF function. For instance, the 
mutation of a TCF7L2-binding site within an enhancer of MYC reduces the expression 
of MYC, and ultimately results in decreasing risk for tumorigenesis in the colon [34]. 
Additionally, since the main function of TFs is DNA binding, modification or mutation 
of regulatory DNA leads to the alteration of TF binding sites, and results in the altered 
expression pattern and occurrence of disease. As an example, the recurrent somatic 
mutations in the TERT promoter in specific types of human cancers lead to enhanced 
expression of telomerase[35]. 
 
1.3 Biological characteristics of pancreatic cancer 
1.3.1 The overview of pancreatic cancer 
The overall five-year survival rate for people with pancreatic cancer is 9% according 
to the latest statistics of pancreatic cancer provided by American National Cancer 
SEER in 2019. About half (52%) of patients are diagnosed at a distant stage which is 
a late stage, and the five-year survival rate of this stage is only 3%. Surgery, radiation 
therapy, and chemotherapy are treatment options that may extend survival and/or 
relieve symptoms, but still, pancreatic cancer is often considered as incurable [36].  
 
1.3.1.1 Epidemiology and risk factors of PDAC 
Pancreatic cancer refers to pancreatic ductal adenocarcinoma (PDAC) since around 
95% of pancreatic cancers are classified as exocrine tumors, of which PDAC is the 
most common malignant neoplasms. For the anatomy of the pancreas, the pancreas 
mainly consists of 5 different cell types including acinar cells which secrete digestive 
enzyme, ductal cells which secret bicarbonate, endocrine islets which secrete 
hormone, centro-acinar cells which are the geographically bridge between acinar and 
ductal cells, quiescent and activated pancreatic stellate cells which can express matrix 
molecules inducing pancreatic fibrosis [37]. Other less common exocrine tumors are 
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acinar cell carcinoma, intraductal papillary mucinous neoplasms (IPMNs) and 
mucinous cystic neoplasms (MCNS). The pancreatic endocrine neoplasms are called 
Pancreatic Neuroendocrine Tumors (PNETs), which are rare pancreatic neoplasms 
[38]. PNETs grow slower compared with the other neoplasms and are often best 
treated surgically. 
 
As for risk factors of pancreatic cancer, age, living habit, family inheritance, and 
medical history are mainly involved. Age is the determining reason for the occurrence 
of pancreatic cancer. Healthy lifestyle is important for preventing the pancreatic cancer. 
Tobacco smokers have a twofold to a threefold higher risk of neoplasm incidence than 
non-smokers. Some nutritional and dietary factors, including high intake of (saturated) 
fats, low intake of vegetables and fruits and consumption of red and processed meats, 
are also associated risks. Additionally, heavy alcohol consumption is also considered. 
In terms of disease association, obesity, chronic pancreatitis, and diabetes mellitus 
are risk factors for pancreatic cancer. Furthermore, a family history of pancreatic 
cancer and certain genetic syndromes are also the risk factors [36].  
 
1.3.1.2 Diagnosis and therapy of PDAC 
Pancreatic tumors are often considered as incurable. One of the reasons is the lack 
of reliable diagnostic biomarkers for early detection. Serum cancer antigen 19–9 
(CA19-9) is the most widely used biomarker to monitor disease progression, 
recurrence and/or therapy response. However, CA19-9 can’t be used for early 
pancreatic cancer diagnosis because of the low sensitivity and specificity [39]. 
Additionally, a panel of mutated genes such as mutated KARAS or mutated TP53 from 
circulating tumor DNA could be applied as a non-invasive early diagnostic test since 
this panel has been detected at the time of diagnosis in 43% of patients with localized 
disease [40]. Furthermore, the increasing circulating branched chain amino acids can 
be indicators for the pancreatic cancer of early-stage [41]. Moreover, in terms of 
diagnosis, clinically, imaging must be conducted. MultiDetector CT (MDCT) or even 
more sensitive method MRI is the commonly used imaging method. However, 
pathology is still the gold standard for the diagnosis when the pancreatic cancer is 
suspected.  
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Over the past decades, little improvements have been made to increase the 5-year 
survival rate. For the treatment, patients are classified according to the tumor stage 
and performance status based on Eastern Cooperative Oncology Group (ECOG) 
score. Different treatments for patients are suggested accordingly. In terms of 
resectable tumors, the surgery is followed by adjuvant chemotherapy (gemcitabine 
plus capecitabine). This combination chemotherapy showed an improved 5-year 
overall survival rate over gemcitabine monotherapy [42]. As for borderline resectable 
and locally advanced tumors, and unresectable tumors, neoadjuvant chemotherapy 
(e.g. FOLFIRINOX or radiochemotherapy) is applied. In the case of patients in the 
metastatic stage, FOLFIRINOX and nab-paclitaxel–gemcitabine are standard 
treatment options when patients are in good performance status. Besides the standard 
of care, the newer strategies for the treatment are embraced. Pathway-specific 
targeted therapies have failed since signaling in pancreatic cancer is complex and 
other strategies (e.g. therapies targeting and modulating the stroma and tumor 
microenvironment, immunotherapies, novel biomarker in early stage, multimodal 
imaging, and identification of druggable key signaling hubs) are in the development 
which might reboot the pancreatic treatment options in the future [43].  
 
1.3.1.3 The microenvironment of pancreatic cancer 
 
Figure 1.2 Tumor Microenvironment 
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It mainly includes fibroblasts, immune cells, tumor cells, and extracellular matrix (ECM). Tumor cells 
generate signals including dysfunction and death of immune cells, the immune cells are a source of 
signals promoting the activation of cancer associated fibroblasts which secrets ECM and promote the 
growth of tumor cells. (Figure was modified from [44].) 
 
When PDAC is studied, the microenvironment, and heterogeneity are always 
challenging topics. The complexity of interactions between the microenvironment and 
cancer cells still remains elusive. While this complexity also provides new 
opportunities for the exploration of therapy.  
 
What is the microenvironment of pancreatic cancer?  In the site of lesions, the tumor 
cells interact with the stroma, and the tumor cells promote the development of the 
stroma. On the other hand, the stroma supports the growth and metastasis of the 
tumor cells, blocks the treatment of the tumor cells, and has an effect on the chemo-
resistance as well as recurrence of the disease. The stroma consists of the cellular 
component (pancreatic fibroblasts, pancreatic stellate cells, vascular cells, infiltrating 
inflammatory/immune cells, endothelial cells and neuronal cells) and the acellular 
component (extracellular matrix proteins including collagenous and non-collagenous 
proteins; soluble proteins such as cytokines and growth factors).  In terms of cellular 
component, the cells mainly have 2 origins, one type is called cells of hematopoietic 
origin which mainly are immune cells that arise in the bone marrow, the other type is 
called cells of mesenchymal origin which mainly include fibroblasts, myofibroblasts, 
mesenchymal stem cells, adipocytes and endothelial cells [45]. 
 
Pancreatic fibrosis is a characteristic pathological feature of PDAC and chronic 
pancreatitis that can disrupt pancreatic exocrine and endocrine function irreversibly 
[46]. Pancreas cancer environment is crucial for the development of pancreatic fibrosis. 
In the 1990s, in human pancreas, people firstly identified a new cell type displaying 
the expression of α- smooth muscle actin (α-SMA) and synthesis of ECM proteins 
which are the characteristics of activated myofibroblasts in the human pancreas [47]. 
The quiescent pancreatic stellate cells can be activated by soluble factors including 
IL-1, IL6, TNF-a, TGF-b1 and activin1 which are released from platelets, macrophages, 
pancreatic acinar cells and endothelial cells in the inflamed pancreas, and the 
activation can also be achieved by in vitro cell culture [48]. The activated stellate cells 
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lose the retinoid-containing fat droplets, change to myofibroblast-like cells expressing 
α-SMA, produce large amounts of the ECM proteins as well as synthesize cytokines 
such as TGF-β1, activin A and IL-1[48]. In the clinic, studies have shown an 
association between the activated PSCs and poor clinical outcome [38]. These in vitro 
and in vivo evidences are accumulated and indicating that the activation of PSCs plays 
a key role in the development of stromal cancer compartment and pancreatic fibrosis. 
Thus, targeting signaling pathways that play a crucial role in PSC activation is a 
promising therapeutic strategy that may inhibits the pancreatic fibrosis.  
 
The crosstalk between the immune cells (T cells which mostly are CD4+ positive, 
myeloid-derived suppressor cells, macrophages, and mast cells) and the tumor cells 
also becomes a focus of attention. In summary, the immune infiltrating indicates an 
immunosuppressive phenotype. The monocytes from the bone marrow are recruited 
and transformed into macrophages by the PDAC tumor cells. Macrophage polarization 
is differentially controlled by a complex network of signaling effectors. There are 
normally two types of activated macrophages, one is M1 which are classically 
activated by interferon γ (IFNγ) with lipopolysaccharide (LPS) or tumor necrosis factor 
(TNF), the other is M2 type which includes M2a subtype alternatively activated by IL-
4 and IL-13, M2b subtype activated  by immune complex and Toll-like receptor (TLR) 
ligands, and M2c subtype activated by IL-10 and glucocorticoids [49]. It was reported 
that M1high/M2low correlated significantly with longer survival period, and M1/M2 ratio 
can be used as a prognosticator [50]. In general, M1 macrophages are so-called tumor 
suppressive macrophages which normally promote T-helper-1 (Th1) responses, and 
M2 macrophages are namely tumor-promoting macrophages that promote T-helper-1 
(Th1) responses. The phenotype state of macrophage is changing over the 
development of a tumor. When a tumor is initiated, M1 type is mainly abundant in 
chronic inflammatory sites. During the progress of the cancer, M2 type takes the 
dominant part [51].  
 
In addition to harboring carcinoma cells, immune cells, and cancer-associated 
fibroblast, the tumor microenvironment also comprises cancer stem cells (CSCs). 
Even though CSCs is a minority subpopulation within tumors, it plays an important role 
in initiating and driving the tumor growth. CSCs have been identified in 1994, and they 
have been revealed in the pancreas in 2007. Afterward, the knowledge of CSC’s 
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function is expanded. One of the explanations for the presence of CSCs is that they 
are induced by epithelial to mesenchymal transition (EMT) program. The EMT is 
induced by various signals from the tumor stroma including the ECM and secreted 
factors. Such signaling induces the expression of a certain set of EMT-TFs including 
SNAIL, TWIST, and ZEB family of transcription factors and thus changes the 
phenotype of the carcinoma cells. CSCs share phenotypes and characteristics of 
normal stem cells, including self-renewal which is an indicator of the tumor cell 
heterogeneity and maintains the CSC pool. Additionally, CSCs also divide and 
generate more CSCs or the multiple cell lineages within the tumor bulk. They are 
normally located near vessels in a perivascular niche or a hypoxia niche, indicating 
that they have close communication with the other component in the 
microenvironment [52]. Moreover, CSCs show the intrinsic resistance to the traditional 
therapeutics because of the quiescent state of stem cells e.g. chemotherapy and 
radiotherapy [53].  
 
The complex microenvironment of PDAC and stroma-rich characteristic of PDAC bring 
challenges of illustrating the signaling of PDAC, targeting precisely, and thus escape 
from the chemotherapy of PDAC. The extent of tumor heterogeneity remains poorly 
understood. With the development of omics technology, the multi-omics level data of 
tumor is applied to decode the genomics and epigenomics of tumor. The complexity 
of omics data reveals the inter-tumor heterogeneity which is indicated by similar 
histology but various genomic aberrations. Additionally, the diverse tumor-harboring 
cell components including tumor or non-tumor cells and acellular components show 
the diverse and versatile intro-tumor heterogeneity. The observed intro and inter 
heterogeneity in tumor challenge precision medicine. To tackle the heterogeneity 
problem, a more comprehensive assessment is needed, which includes a better 
characterization of tumor samples with spatial and temporal variations to monitor 
overtime and identify a reliable target, the consideration of multi-omics data to identify 
the intra and inter-tumor heterogeneity, and involvement of non-invasive biomarker 
monitor and in vivo functional characterizations [54].  
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1.3.2 The general molecular biology of pancreatic cancer 
Genetic and epigenetic alterations have an influence on tumor progression and 
chemotherapy resistance. During pancreatic cancer development, histologically, from 
early precursor lesions (PanIN 1-3 lesions) consequently to PDAC, the histological 
investigations are accompanied by infiltrating immune cells, increasing desmoplastic 
stromal response, multiple involved signaling pathways [55].  
A variety of signaling pathways are involved in multiple stages of pancreatic tumorigenesis from 
PanINs1-3 lesions to PDAC. These histological changes are accompanied by a dynamic tumor 
microenvironment and multiple genetic and epigenetic signaling alterations which lead to an immune 
response against the tumor, tumor cell proliferation, angiogenesis and invasion of tumor cells. Plot was 
modified from [55]. 
 
1.3.2.1 The genetic regulation of pancreatic cancer 
In terms of genomic events, KRAS, CDKN2A, TP53 and SMAD4 are the commonly 
four altered genes in pancreatic cancer but the encoded proteins are no favorable drug 
targets. Point mutations of individual genes are important for the molecular pathology 
of pancreatic cancer. Activating mutations in KRAS are present in over 90% of 
pancreatic cancers [56]. Inactivating mutations of TP53, CDKN2A and SMAD4 occur 
Figure 1.3 Development of pancreatic cancer 
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in 50–80% of pancreatic cancers, whereas other genes, including ARID1A, MLL3 and 
TGFBR2, are mutated in around 10% of tumors [57]. Besides the mutation events, 
copy number alterations and homozygous deletions also play an important role. 
Analysis of data from whole-genomic sequencing and copy number variations (CNV) 
identified new driver genes for pancreatic cancer, such as KDM6A and PREX2. Based 
on the analysis, genes which are important in pancreatic cancer, including TP53, 
SMAD4, CDKN2A, ARID1A and ROBO2 are affected by chromosomal 
rearrangements leading to gene disruption [58]. Furthermore, several gene alteration 
(RBM10 mutations, BRAF mutations) with prognostic significance have been identified 
due to the analysis of whole-exome sequencing [59].  
 
Classifying tumors is the first step towards personalized treatment. According to 
diverse omics data analysis, different classifications of pancreatic cancer have been 
suggested. The analysis of transcriptomics data revealed four subtypes of pancreatic 
cancer: Squamous, pancreatic progenitor, immunogenic and aberrantly differentiated 
endocrine exocrine (ADEX) pancreatic cancer that correlate with histopathological 
characteristics [60]. Three highly distinct metabolic subtypes of PDAC could be 
identified by the metabolite profiling: Reduced proliferative capacity, glycolytic and 
lipogenic [61]. Moreover, PDAC has been classified into four subtypes with potential 
clinical significance (termed stable, locally rearranged, scattered and unstable) based 
on the patterns of structural variations [58]. The identified subtypes provide a solid 
foundation for novel promising therapeutic strategies, targeting pancreatic cancer.  
 
Signaling pathways of pancreatic cancer are complex due to multiple nodes and 
complex crosstalk. Analysis of 24 pancreatic tumors’ transcriptomes with next-
generation sequencing-by-synthesis technologies revealed twelve cellular signaling 
pathways which were altered in 67%-100% of the tumors. These core regulatory 
processes or pathways are: Apoptosis, DNA damage control, regulation of G1/S 
phase transition, hedgehog signaling, homophilic cell adhesion, integrin signaling, C-
Jun N-terminal kinase signaling, KRAS signaling, regulation of invasion, small 
GTPase-dependent signaling (other than KRAS), TGF-β signaling and Wnt /Notch 
signaling [62]. Furthermore, an exome sequencing together with copy number analysis 
revealed diverse somatic aberrations in genes described traditionally as embryonic 
regulators of axon guidance. Particularly SLIT/ROBO signaling pathways are also 
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involved in the carcinogenesis of pancreatic cancers [63]. Moreover, an integrated 
genomic analysis identified 32 recurrently mutated genes which were enriched into 10 
pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signaling, G1/S transition, SWI-
SNF, chromatin modification, DNA repair and RNA processing [60]. Whole-exome 
sequencing have identified high-frequency alterations in Wnt signaling, chromatin 
remodeling, hedgehog signaling, DNA repair and cell cycle processes [59]. All these 
provide a better understanding of the molecular pathology of pancreatic cancer.  
 
1.3.2.2 The epigenetic regulation of pancreatic cancer 
The development of pancreatic cancer is not only attributed by mutations, such as 
activating mutations of KRAS or inactivation of the tumor suppressor genes TP53 and 
CDKN2A. More recently, the important role of epigenetic regulations for PDAC 
became more evident. Epigenetic changes including DNA methylation, histone 
modification and non-coding RNA alterations can lead to the alterations in gene 
expression without changing the DNA sequence. These changes result in silencing of 
important tumor suppressor genes, cell cycle checkpoints, hyperactivation of 
oncogenes, and growth stimuli.  
 
DNA methylation is a process in which DNA methyltransferases (DNMTs) add a 
methyl group to the 5’ carbon of the cytosine pyrimidine ring. This modification 
normally occurs in the region of cytosine-guanine dinucleotides (CpGs). The 
expression level of DNMTs increases in pancreatic cancer, representing a potential 
therapeutic target [64]. In general, DNMT inhibitors contain two different types, 
nucleoside analogs such as 5-Azacytidine and 5-aza-2’-dC [65]; non-nucleoside 
inhibitors such as RG108, SGI-1027, hydralazine [66].  
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Concerning the regulation of expression, besides the DNA sequence itself, DNA methylation, chromatin 
interaction, and histone modification are involved in the regulation of transcription. Figure was adapted 
from [4]. 
 
It is known that aberrant DNA methylation is associated with transcription regulation. 
Generally, in the early stage of tumor, DNA hypermethylation of gene promoter CpGs 
downregulates the transcription of tumor suppressing genes [67]. While, DNA in 
cancer cells was hypomethylated in the late stage, this hypomethylation is related with 
genomic instability, activation of oncogene and activation of silenced transposable 
sequences [68, 69]. Regionally, DNA methylation in gene bodies may facilitate 
transcription, elongation and regulate splicing events [70].  
 
Histone modification is more complex than DNA methylation. Nucleosome which are 
the fundamental unit of chromatin, is 145–147 base pairs of DNA-wrapped around a 
histone protein octamer (dimers of H2A, H2B, H3 and H4) [71]. DNA-associated 
histone modifications with different degrees of modification (e.g., mono-, di-, and 
trimethylation) include phosphorylation, methylation, acetylation, ubiquitination and 
sumoylation [72]. Modifications of histones determine the configuration of the 
chromatin, and transcriptionally open or closed structured chromatin changes 
Figure 1.4 Beyond sequence 
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accessibility of transcription-associated protein with DNA, thus consequently influence 
the transcription of gene [67]. 
 
Histone acetyltransferases (HATs) transfer an acetyl group from the acetyl coenzyme 
A to the ε-amino group of lysine such as CREBBP (cAMP response element-binding 
protein), p300 and p300-CBP-associated factor (P/CAF). Thus, the histone gets 
acetylated and the gene transcription is activated. The reverse reaction is called 
deacetylation which is performed by histone deacetylases (HDACs). The 
deacetylation leads to closed chromatin [73].  
  
In terms of histone methylation, the lysine, arginine, and histidine residues at the 
amino acid side chains are modified by histone methyltransferases (HMTs) and 
histone demethylases (HDMs). The well-characterized histone activation markers are 
H3K4me1/2/3, H3K9me1, H3K27me1 and H3K79me1/2/3. In contrast, the histone 
inactivation markers are H3K9me2/3, H3K27me2/3, H3K79me3 [74]. 
 
Another class of histone modification is histone ubiquitination. It influences the 
pancreatic homeostasis and pancreatic cancer tumorigenesis. This type of histone 
modification mainly occurs on H2A and H2B which alters nucleosome dynamics and 
indirectly affect other histone modifications. DNA damage can trigger H2A 
ubiquitination which is followed by the recruitment of downstream DNA damage repair 
proteins. H2B ubiquitination is crucial for the double strand break repair and 
deubiquitylation plays a role in transcription-coupled repair [75]. 
 
Besides the core canonical histones (H3, H4, H2A, H2B), mentioned previously, there 
are multiple variants of each core canonical histone representing specific structural 
and functional features. For example, the histone variants H3.3 and H2A.Z may be 
involved in histone exchange or nucleosome eviction during chromatin remodeling [76]. 
Additionally, the histone variants could also indicate the potential accessible regions 
of the genome which are potentially the regulatory element regions [77] [78] [79].  
 
The integrative analyses of chromatin immunoprecipitation-sequencing (ChIP-seq) on 
multiple histone modifications, RNA-sequencing (RNA-seq), and DNA methylation 
profiling highlight the epigenomic landscapes for PDAC subtypes and thus, suggested 
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that epigenetic changes have an effect on carcinogenesis as well as heterogeneity. A 
clear association between the methylome, transcriptome, and chromatin state-based 
clustering could be shown. Moreover, the landscapes are regulated by different 
membrane-to-nucleus pathways and can predict the patient outcomes regarding the 
relative aggressiveness and survival potential [80].  
 
All these observations demonstrate that genetic regulations together with epigenetic 
modifications contribute to the development of pancreatic cancer.  
 
1.4 Why identification of TFs that specifically bind methylated 
recognition sites? 
1.4.1 The impact of methylation in the carcinogenesis of pancreatic 
cancer 
Alteration of methylation at promoter region is associated with expression 
dysregulation of many cancer-regulated genes and thus the aberrant DNA methylation 
is considered as one of the driving factors of carcinogenesis [81] [82]. In pancreatic 
cancer, the most frequently methylated promoters are promoters of APC (50%), 
BRCA1(46%), p16INK4a (35%), p15INK4b (35%), RARβ (35%), and p73 (33%), and 
the methylation of at least one gene mentioned above have showed in 94% of the 
pancreatic cancer cases [83]. Furthermore, CDKN2A [84] is inactivated by 
hypermethylation. The whole genome methylation profiling reveals that the aberrant 
gene methylations are enriched in the following gene loci and signaling pathways: 
TGF-β, WNT, integrin, Slit Guidance Ligand (SLIT)-Roundabout Guidance Receptor 
(ROBO) signaling, cell adhesion and stellate cell activation pathways. Additionally, the 
SLIT-ROBO, ITGA2 and MET signaling is epigenetically deregulated [85]. Moreover, 
the hypermethylation in the promoter region of miRNA that are repressed in cancer is 
a common mechanism in all human tumors [86].  
 
In the microenvironment, various cell types contain almost identical copy of the 
genome, while the transcriptome and phenotype of each is unique. This can’t be 
explained only by the genomic information of the cells but by integrative information of 
the epigenome. Different cell events in microenvironment, such as PSC activation, 
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macrophage polarization, stem cell renewal, differentiation, and the dynamic plasticity 
of the cells come to the focus of the attention. Since the reprograming is changing with 
response to the various stimuli in the microenvironment, the epigenetic factors 
including histone modification, DNA methylation and non-coding RNAs, regulate the 
gene expression at an appropriate level, time and place. Finally, this process 
determines cell fates, such as the disease phenotype or non-disease state. As 
reported previously [80], the epigenomic landscapes highlight the PDAC heterogeneity, 
predict survival, and classify the molecular pathobiology subtypes. This provide an 
insight into a new therapy strategy which focus on developing new drugs that target 
the factors involved in the epigenetic regulation.  
 
1.4.2 Integrative analysis of expression and methylation 
Most eukaryotic genes are controlled at the level of transcription. In PDAC, an 
integrated analysis of DNA methylation and mRNA expression data indicated that 98 
genes that were silenced by DNA methylation, might exert important roles in the 
development of cancer [87]. Moreover, the fact that hypomethylated VAV1 promoter 
leads to increased gene expression, suggests roles of DNA hypomethylation in 
upregulation of gene expression [88]. The methylation of promoter is generally 
considered to repress gene expression since methylated promoter could block the 
binding of TFs and elicit subsequent higher binding affinity of MBDs with methylated 
DNA sequences [67]. Recent studies indicate the impact of cytosine methylation on 
the DNA binding of TFs that lack the MBDs is not always negatively [89]. Yu Liu et. al 
[90] systematically revealed the promoter CpG methylation-dependency of 
transcription regulation across 21 cancer types. The mechanism of methylation-
dependent TF regulation is complex. It is not as simple as we thought before that 
promoter methylation is the potent repressor for the gene expression.  
 
1.4.3 The impact of methylation on the binding of TFs 
TFs act as the readers of the DNA, while how about the DNA with modification? 
Traditionally, only TFs with a methyl-CpG (mCpG)-binding domain (MBD) is able to 
recognize and bind methylated CpG dinucleotides [91] [92]. In mammals, the MBD-TF 
family includes 5 known proteins, MeCP2 (methyl-CpG-binding protein 2), 
MBD1(methyl-CpG binding domain 1), MBD2, MBD3 and MBD4. In this family, only 
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MBD3 does not bind to methylated DNA, while all the other MBD proteins bind to 
methylated DNA in a non-sequence-specific way [93] [94]. However, over the past 
decades, more and more evidences show that some TFs lacking MBDs are also 
capable of binding with methylated DNA [89]. In the past 5 years, the methylated motifs 
of many TFs lacking MBDs have been identified systematically by diverse approaches. 
Data from protein microarray suggests that 47 TF proteins lacking MBDs could bind 
the methylated CpG sites, and some of them could recognize both methylated and 
non-methylated with distinct sequence similarities [89]. Data from methyl-SELEX 
reveals that CpG methylation influences binding of most TFs to DNA, while the effects 
are either negative or positive to regulate gene expression. Global analysis with 542 
TFs indicates that many developmentally important TFs (homeodomain, POU and 
NFAT proteins) prefer to bind with mCpG sites. This conclusion facilitates future 
analysis of the role of DNA methylation on cell differentiation, chromatin 
reprogramming, and transcription regulation [23]. Furthermore, more and more 
evidences have showed that TFs could recognize the methylated motif and regulate 
diverse biological events including activation of gene expression [95], recruiting 
additional TFs and cofactors [96] and regulating splicing regulation events {Maunakea, 
2013 #1335}. Systematical integrative analysis pipeline has revealed the methylation-
dependent regulation machinery in 21 cancer types. The coupled CpG sites and TFs 
could also stratify the cancer subtypes with different prognoses [90]. Taken together, 
the knowledge on how TFs regulate gene expression has been widely expanded. 
Traditionally, it’s accepted that TFs bind non-methylated DNA motifs in open 
chromatin regions because the DNA methylation could block such interactions; while 
nowadays the new scenario of TFs-DNA interactions uncovers that DNA methylation 
alternatively provide new binding sites for TFs lacking MBDs.   
 
1.5 Strategies for studying the regulation of TFs 
1.5.1 Experimental approaches for identification of binding 
specificities of TFs 
To answer the question that what are the biological consequences upon the binding 
of TFs to methylated DNA, the first step is to identify the binding motif of TFs. The 
binding property can be studied by a wide variety of techniques both in vitro and in 
vivo. Different methods are selected based on the purpose of study. 
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Electrophoretic Mobility Shift Assay (EMSA) [97] is used to determine the affinity of 
TFs to different DNA fragments with known sequences. This assay is a gel-based and 
comply with the different mobility between large molecules with various size and 
charge. For example, if the TF could recognize and bind the DNA molecule, the DNA-
TF complex will move slower than the DNA or the TF molecule alone because of the 
bigger size. Thus, by comparing the mobility of TF-incubated DNA with the DNA 
molecule control alone, one can determine the TF’s preference to the tested DNA. 
However, it cannot be used to identify the novel binding motif of TFs, and the 
throughput of this assay is quite low. In terms of the high throughput in vitro assay, 
SELEX and PBM are illustrated below in detail.  
 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX) [98] is used to 
study the TF binding sites by massively incorporating paralleled sequencings. Initially, 
random oligos are synthesized and double-stranded. Afterward, the TFs are 
immobilized and incubated with DNA with the length limit of 25bp. For each round of 
panning, the selected DNA is amplified by PCR and used for next cycle of selection to 
reduce the background. Thus, the specific DNA that TFs bind can be identified by 
sequencing upon the selected DNA get enriched after several rounds of panning. In 
recent years, the application of SELEX is broadened, it can also be used to identify 
the methylated-motif of TFs [23]. Moreover, the TF cooperativity is important for DNA 
binding specificity and effector function. In order to study this topic, SELEX method is 
developed into CAP-SELEX to measure the multimers [99]. However, the bias 
introduced by PCR is difficult to be avoid in this method since the very low affinity sites 
may be lost in the PCR amplification process, or the high affinity sites become 
saturated in the PCR amplification process.  
 
Protein binding microarray (PBM) is an alternative high throughput method to model 
the TF binding specificities. It is either based on the DNA microarray or protein 
microarray. As for the DNA microarray [100], the double stranded DNA is generated 
on the array by recruiting the microarray probes followed by labeling with Cy3-dUTP. 
The array covers all combinations of 8-mer sequences for selection. Then, the in vitro 
expressed and purified TFs are incubated on the microarray. Consequently, the 
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fluorophore-conjugated antibody against the common tag of all TFs is incubated on 
the array to detect the TF binding. Finally, the signal intensity is extracted by reading 
the fluorescence from binding complex between double-strand DNA and protein 
antibody. The signal intensity is used to quantify binding preference of one TF toward 
various DNA motifs. In terms of protein microarray [101], TFs are expressed, purified 
and spotted on the array.  DNA motifs with lengths ranging from 6-34 bp are selected 
and synthesized with conjugated fluorophores. Subsequently, DNA is incubated with 
TF microarray and followed with image scanning and signal acquisition. Besides the 
application in identifying DNA motif, PBM can be also used to the identification of 
methylated DNA motif and multimers [89]. However, DNA-microarray-based PBM has 
been hampered with short probe length (8 bp) in generating the PWM; While protein 
microarray-based PBM is limitedly employed in exploring DNA motifs with known 
sequences and potential binding sites.   
 
All methods mentioned above are used for in vitro assays. In order to identify the 
binding specificity of TFs in different cell types and even in tissues, the combination of 
chromatin immunoprecipitation (ChIP) and next generation high-throughput 
sequencing (NGS), is widely used to study the genome-wide binding region of TFs. 
Briefly, TFs are firstly cross-linked to chromatin DNA after formaldehyde treatment and 
further pulled down using its specific antibody together with its bound DNA, and the 
non-specific bound DNAs are washed away. Next, this pull-down DNA is de-
crosslinked and ready for sequencing. However, there are several concerns that might 
limit wide application of ChIP-seq. Firstly, from the experiment’s point of view, high-
quality ChIP result is highly dependent on antibody quality, while ChIP-grade 
antibodies are not easily available. Secondly, ChIP excludes the equilibrium binding 
due to the use of cross-linkers. Thirdly, ChIP also includes the indirect binding. 
Fourthly, binding is highly influenced by chromatin state, i.e. most TFs prefer to bind 
in the region of open chromatin. Finally, the biases in the sequence content of the 
genome could also interfere the ChIP-seq result [16].  
 
Moreover, many other methods are designed to identify the TF specificity. The table 
listed below summarizes all the methods. 
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Figure was adapted from [16]. 
Besides various experimental methods to identify the motif of transcription factors, an 
in-silico approach is also widely used to map transcription binding sites. MEME suite 
is a collection of tools for the discovery and analysis of sequence motifs [102]. For 
example, MEME-ChIP facilitates refinement in discovering motifs from raw data of 
ChIP-seq. If motifs are known, Find Individual Motif Occurrences (FIMO) is an ideal 
Figure 1.5 Experimental methods for determining and validating TF-binding specificities 
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tool for finding evidences of the provided motifs in a sequence. Additionally, in order 
to interpret the functional role of DNA binding motifs, Gene Ontology for MOtifs 
(GOMO) is possible to be used. In such a way, comprehensive information of motif 
can be acquired without experiments, which provides a direction for the next steps of 
projects.  
 
1.5.2 In vitro expressed protein binding microarray  
Protein microarrays cover hundreds to thousands of protein molecules which can be 
used for the protein profiling analysis and functional screening. Protein profiling 
analysis is normally based on the antibodies which are immobilized on the array and 
could specifically recognize antigens from different types of samples such as serum, 
cell lysates, etc. In terms of functional screening, different types of functional proteins 
or protein domains spotted on the microarray could be used to screen interactions with 
proteins, peptides, nucleic acids, intact cells, and various types of smaller ligands [103]. 
To produce the protein microarray, one way is to spot recombinant proteins directly 
on the microarray. Alternatively, protein microarrays can be generated with the help of 
cell-free expression system. Cell-free-based protein microarrays utilize the cell lysates 
from prokaryotic or eukaryotic cells which contain all the essential components for in 
vitro transcription and translation of the template DNA or RNA [104]. Multiple cell-free 
protein microarray technologies are available, such as the original ‘Protein In Situ 
Array’ (PISA) [105], the ‘Nucleic Acid Programmable Protein Array’ (NAPPA)[106], the 
‘DNA Array to Protein Array’ (DAPA) [107] or production by the ‘multiple spotting 
technique’ (MIST) [108]. For different versions of cell-free protein microarray, in 
general, the production starts with templates preparation. Briefly, gene sequences are 
amplified by PCR to introduce the functional elements, such as promoter, ribosomal 
binding site (RBS), epitope tags and other experimentally useful components. The 
templates are spotted on the arrays and incubated with cell-free mixture. The success 
of the protein expression can be detected by fluorophores-conjugated antibodies that 
are able to recognize the epitopes in the N and C terminal of the expressed proteins 
[109]. Furthermore, several factors are needed to be considered for the development 
and optimization of cell-free protein microarray, such as surface and immobilization 
chemistry, different cell-free systems and mass transport limitations [103]. 
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The complete human genome sequence was published in 2001 [110]. For the human 
proteome, around 20687 protein coding genes are collected in the major human 
genome databases, such as Ensembl, RefSeq, UNSC, and GENCODE [111]. Proteins 
play key roles in many cellular networks, metabolism and enzyme regulation, and 
signal transduction [112]. To better understand the functional role of the encoded 
proteins in a view of altered genome in patients, the proteome-based analysis is 
central. The complexity of human genome poses a significant challenge to translate 
genomics to proteomics at the same time in quantitative view. Cell-free protein 
microarray provide a complementary approach to understand the proteome. It is 
challenging for some proteins on the array to retain their native three-dimensional 
structure. However, the exposed epitopes have sufficient quality for protein interaction, 
and further functional validations by low-throughput gel-based methods or 
immunoassays are needed [103]. With the high-throughput technology, thousands of 
proteins can be analyzed at the same time by means of protein microarray. The cell-
free expression helps to avoids the tedious work of protein expression and purification. 
As such, cell-free protein microarray is a powerful tool for the study of protein profiling 
analysis and functional screening. 
 
1.5.3 The functional study of TFs 
However, knowing the binding specificities of TFs is not sufficient to decipher the 
transcription regulation events and transcriptome network. The properties of cis-
regulatory elements and transcription factors help us to understand better about the 
modulation of the transcription. In terms of genetic level, DNA mutation can affect TF 
binding and the expression level of TF itself. In terms of epigenetic level, three types 
of epigenomic regulation may affect TF binding, such as DNA methylation, histone 
modification resulting in the accessibility of chromatin and histone variant. These 
genetic mutations or epigenetic modification may inactivate one of the two copies of a 
gene, reducing the gene expression level or activate the gene/mutant gene expression 
level resulting in abnormal phenotype.  
 
Promoters play central role in the regulation of gene expression; the classical way to 
study how the gene expression is regulated, is to identify the core promoter sequences 
that drive or initiate the transcription of one given gene. In order to achieve this, 
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identification of the TF’s motif in the promoter region is only the first step in decoding 
the gene regulation. Additionally, the mutagenesis, and change of methylation level 
are involved to identify TF binding sites. Next, the manipulation approaches that 
control TFs expression, luciferase assay and ChIP assay are utilized to further verify 
the interaction between the TFs and the targeted promoter. With the expanded 
knowledge of cis-regulatory elements, multiple and or remote enhancers which 
contribute to the gene regulation are also taken into consideration to study the 
regulation of the transcription.  
 
Breakthroughs of array and NGS-driven technologies have promoted understanding 
of human genome and mechanisms related to gene expression regulation. Firstly, the 
expression patterns of multiple genes at the same time can be achieved by the gene 
array and RNA-seq technology. The global gene expression profiling can reveal the 
effect of particular signaling pathway. Additionally, the genome-based technology 
coupled with chromatin immunoprecipitation (ChIP) determine the profiling of TF 
binding sites, TF-cofactor, histone modification patterns along with nucleosome 
positions [113]. The rapid development of sequencing method from microarray-based 
methods to next-generation sequencing (NGS) boosts the field of gene expression 
research. High throughput TSS sequencing, ChIP-seq, MNase and DNase I 
hypersensitive sequencing provide a set of evidences that cis-regulatory elements are 
widely dispersed in the mammalian genomes, such as at large distances from the 
TSSs of the putative targeted gene, in the intergenic regions.  
 
The topology of chromatin loop needs to be considered since many regulatory 
elements are not immediately next to but physically contact the target genes via 
looping. Chromosome confirmation capture (3C) have been developed to study the 
chromatin looping and further understand how TFs regulate the transcription [114, 
115]. Based on 3C, more advanced technologies 4C, 5C, 6C, Hi-C and ChIA-PET 
have also been developed to better understand the intrachromosomic interaction [116, 
117]. With the development of NGS technology, 3C linked with NGS and ChIP resulted 
in the following technologies, 3C-Seq, 4C-Seq, 5C, ChIA-PET and Hi-C. These 
technologies produced the possibility to map the interactions about the identified cis-
regulatory elements and promoters. Additionally, it can also reveal the organization of 
higher-order chromatin structure in the nucleus.  
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1.5.4 The strategies for this study 
This study aims to identify the TFs which recognize the methylated binding sites, while 
knowing the binding specificities is not enough to decipher the methylation-dependent 
regulation events. To reveal the complexities of gene regulation, in my case, many 
factors need to be considered. In the following part, the strategies used in this study 
is summarized. In the beginning of the study, a set of data provided useful information 
for identifying the genes potentially regulated by the aberrant methylation in the 
promoter region, including methylation and expression profiling from cells and tissues 
and prior knowledge of promoter location. However, identifying the core promoter 
driving the expression of genes remains very cumbersome since prior knowledge of 
promoter location was not enough to decipher the complexed gene regulation. That’s 
why I started to focus more on NFATc1 which was identified from protein microarray 
and showed the binding preference to methylated DNA sequence. In order to identify 
the targets of NFATc1, the mRNA profiling of NFATc1-knockdown cell samples has 
been assessed by microarray to investigate the global gene profiling which was 
regulated by NFATc1. In order to identify the core promoter driving the gene 
expression, in silico analysis with known TFBSs has been employed to analyze the 
pre-defined promoter region. Afterward, luciferase assay and ChIP assay have been 
utilized to verify the interaction between NFATc1 and the promoter of target genes. In 
vitro methylation and demethylation treatment have been used to validate the 
methylation’s effect on the binding of NFATc1. Consequently, a link between 
methylated TF motifs and the target gene was constructed. With a better 
understanding of the effect of methylation on the transcription factor binding and the 
function of NFATc1, the chromatin structure and the interaction between proposed 
enhancer and target genes needed to be studied further to reveal the complex 
methylation-dependent expression regulation by NFATc1.   
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2 Material 
2.1  Antibodies 
Product Cat. No. Manufacturer 
Mouse Anti-V5-Cy3TM Monoclonal Ab V 4014 Sigma-Aldrich, Germany 
Penta·His Alexa Fluor647 Conjugate 35370 Qiagen, Germany 
Anti-NFATc1 Ab SC-7294 X 
Santa Cruz 
Biotechnology, Inc., 
Germany 
NFATc1 Antibody (7A6) MA3024 Life Technologies, USA 
Anti-GAPDH Ab G9295 Sigma-Aldrich, Germany 
Normal mouse IgG SC-2025 Vector Laboratories, USA 
Control Antibodies, Mouse IgG VEC-I-2000 Vector Laboratories, USA 
Anti-mouse IgG(H+L) Peroxidase VEC-PI-2000 Vector Laboratories, USA 
Anti-rabbit IgG(H+L) Peroxidase VEC-PI-1000 Vector Laboratories, USA 
  
2.2 Reagents 
Product Cat. No. Manufacturer 
HotStar Taq Polymerase  203203 Qiagen, Germany  
Nuclease-free water AM9939 Thermo Fisher Scientific, USA 
NEB Buffer 2 B7002S NEB, USA 
HaltTM Protease &  
Phosphatase inhibitor 
78443 Thermo Fisher Scientific, USA 
Fast SYBRâ Green 4385612 Thermo Fisher Scientific, USA 
QuantiTect SYBRâ Green 204141 Qiagen, Germany 
RIPA Lysis and  
Extraction Buffer 
89900 Thermo Fisher Scientific, USA 
Benzonase Nuclease 70746-4 Merck KGaA, Germany 
4X Laemlli sample buffer 161-0737 BIO-RAD Laboratories, USA  
Pierce™ ECL Western  
Blotting Substrate 
32106 Thermo Fisher Scientific, USA 
Lipofectamine® 2000  11668030 Thermo Fisher Scientific, USA 
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T4 polynucleotide kinase M0201S NEB, USA 
T4 DNA Ligase buffer B0202S NEB, USA 
BsmbI R0580S NEB, USA 
Quick Ligation™ Kit M2200S NEB, USA 
One Shot™ Stbl3™  
Chemically Competent E. coli 
C737303 Thermo Fisher Scientific, USA 
Ampicillin Natriumsalz K029.2 Carl Rot, Germany,  
TurboFect R0531 Thermo Fisher Scientific, USA 
Polybrene TR-1003 Sigma-Aldrich, Germany 
Q5â reaction system M0491S NEB, USA 
EcoRI enzyme R0101S NEB, USA 
BamHI enzyme R0136S NEB, USA 
In-Fusionâ HD cloning system  638909 Clontech Laboratories,  
Takara, Japan 
Resazurin 10684882 Acros Organics by Fisher 
Scientific, USA 
BstUI ER0921 New England Biolabs GmbH 
FastDigest BgIII FD0084 Thermo Fisher Scientific, USA 
GeneRuler 1kb ladder SM0312 Thermo Fisher Scientific, USA 
GeneRuler 100bp Plus Ladder SM0323 Thermo Fisher Scientific, USA 
GeneRuler Low Range Ladder SM1191 Thermo Fisher Scientific, USA 
M.SssI M0226 L New England Biolabs GmbH 
OneShot PIR1 
(chemically competent cells) 
C1010-10
  
Invitrogen by Thermo Fisher 
Scientific Inc., USA 
Quick Ligase  M2200 New England Biolabs GmbH 
X-Gal 2315.1 Carl Roth GmbH & Co. KG, DE 
Zeocin R25001 Life Technologies, USA 
 
2.3 Kits 
Product Cat. No. Manufacturer 
S30 T7 High-Yield Protein  L1110 Promega, USA 
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Expression Kit 
AllPrep DNA/RNA Mini Kit 80204 Qiagen, Germany,  
Illustra MicroSpin G-25 Columns 27532501 GE Healthcare, USA 
ProtoScript® First Strand  
cDNA Synthesis kit 
E6300S NEB, USA 
Keratinocyte-SFM Medium kit 17005042 Thermo Fisher 
Scientific, USA 
PierceTM BCA Protein Assay kit 23225 Thermo Fisher 
Scientific, USA  
NucleoTrap® kit 740584 Machery-Nagel, 
Germany 
QIAprep Spin Miniprep kit 27104 Qiagen, Germany  
PureLink® PCR Purification Kit K310001 Life technology, USA 
QIAquick Gel extraction kit 28115 Qiagen, Germany 
Annexin V-Cy5 Apoptosis  
Detection Kit 
ALX-850-254 Enzo Life Sciences, 
USA 
Propidium iodide (PI) P3566 Invitrogen by  
Life technology, USA 
EpiTect Bisulfite Kit 59104 Qiagen, Germany 
EpiTect PCR Control DNA Set 59568 Qiagen, Germany 
SimpleChIP Enzymatic Chromatin 
IP Kit (Magnetic Beads) 
9003 Cell Signaling 
Technology, USA 
S30 T7 High-Yield  
Protein Expression Kit 
L1110 Promega, USA 
NucleoSpin® Plasmid  
Transfection-grade 
740490.50 MACHEREY-NAGEL, 
DE 
The Original TA Cloning® Kit 450030 Invitrogen by Thermo 
Fisher Scientific, USA 
Dual-Luciferase Reporter Assay  E1910 Promega 
 
2.4 Chemicals 
Product Cat. No. Manufacturer 
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dNTP set, Sodium salt M3015.4100 
Genaxxon bioscience 
GmbH, Germany 
Agarose Standard 3810.3 
Carl Roth GmbH & 
Co.KG, Germany 
Tween® 20 P2287 Sigma-Aldrich, Germany 
BSA  
Carl Roth GmbH, 
Germany 
4-(2-hydroxyethyl)-1-  
piperazineethanesulfonic acid  
(HEPES)  
HN77.4 
Carl Roth GmbH, 
Germany 
NaOH 303126.1920 
AppliChem GmbH, 
Germany 
Glutamate Potassium 49601 
Fluka Analytical, Sigma-
Aldrich, Germany 
Magnesium Acetate M5661 Sigma-Aldrich, Germany 
Triton X-100 T8787 Sigma-Aldrich, Germany 
Glycerol G5516 Sigma-Aldrich, Germany 
Dithiothreitol (DTT) R0861 Invitrogen, USA 
Herring sperm DNA 15634017 Invitrogen, USA 
Phenylmethylsulfonylfluoride 
(PMSF) 
8553 
Cell Signaling 
Technology, USA 
TRIS A411.2 
Carl Roth GmbH & 
Co.KG, Germany 
Sodium chloride (NaCl) S9888 Sigma-Aldrich, Germnay 
TRIzol Reagent 15596-018 Invitrogen, USA 
 
2.5 Labware 
Product Cat. No. Manufacturer 
Adhesive PCR Seal 600208 Biozyme, Germnay 
384 Well Lightcycler Platte 72.1985.202 Sarstedt 
Microseal 384-Well Skirted  MSP-3842 Bio-Rad Laboratories, 
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PCR Plates USA 
3D-Epoxy Glas Slides 10400201 PolyAn, Germany 
Hybridization Cassette AHC ArrayIt®, USA 
Nitrocellulose membrane 0.45µm GE10600007 GE Healthcare, UK 
Falcon® 5 mL Round Bottom 
Polystyrene Test Tube, with Cell 
Strainer Snap Cap 
352235 Corning Science, USA 
Camera D7000 Nikon, Japan 
Cell culture flask T175 red 
adherent cells 
12649 Greiner bio one, 
Germany 
Cell culture flasks 25cm 13640 Greiner bio one, 
Germany 
Cell culture flasks 75cm 12667 Greiner bio one, 
Germany 
Cell culture plates-6 well 657160 Greiner bio one, 
Germany 
Cell culture plates-48 well 677180 Greiner bio one, 
Germany 
Cell culture plates-96 well 655180 Greiner bio one, 
Germany 
Cell culture flask T75  
Yellow flask for better adhesion 
90076 TPP Techno Plastic 
Products AG, 
Switzerland 
Syringe filters 25 mm, 0,45µm 514-0063 VWR, USA 
Vivaspin 20 centrifugal 
concentrator (MWCO 30kDa) 
Z614629-12EA Sigma-Aldrich, Germany 
 
2.6 Equipment 
Product Manufacturer 
Nano-plotter  GeSiM 
Orbital shaker NeoLab Migge GmbH, Germany 
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NanoDrop ND-1000 Thermo Fisher Scientific, USA 
Centrifuge 5810R Eppendorf, Germany 
Tecan power scanner Tecan Group AG, Switzerland 
LifeECO thermal cycler BioER Technology Co., Ltd., China 
Centrifuge 2K15 Sigma, Germany 
The Infinite® M200 plate reader Tecan Trading AG, Switzerland 
Heating block Grant Instruments, United Kingdom 
Microcomputer electrophoresis 
 power supply 
Renner GmbH, 
Germany 
Trans-Blot® TurboTM BIO-RAD Laboratories, United States 
Bench-top rocker Phoenix Instrument, Germany 
Image Quant Luminescent Image 
Analyzer LAS-4000 mini 
Fujifilm,  
Japan 
FACSAriaTM III machine BD Biosciences, USA 
FLUOstar Galaxy BMG Technologies, Germany 
Sarstedt TC insert for 24 well plate (8µm) Sarstedt, Germany 
Zeiss Axio Examiner. Z1 Zeiss, Germany 
BD FACSCanto II BD Bioscience, USA 
BD FACSAria III BD Bioscience, USA 
Illumina iScan array scanner Illumina, USA 
Sonoplus-sonicator BANDELIN, Germany 
LightCycler 480 Roche, Germany 
Vi Cell XR cell counter Beckmann Coulter, Germany 
Galaxy 170 S incubator Eppendorf, Germany 
Swing wing Centrifuge R5810 Eppendorf, Germany 
Gel Imaging Workstation Azure biosystems, USA 
Vacuum concentrator Bachofer GmbH, DE 
 
2.7 Media 
Product Cat. No. Manufacturer 
PBS 10010056 Life Technologies 
(Gibco), USA 
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IMDM with phenol red 21980065 Life Technologies 
(Gibco), USA 
DMEM 4.5g glucose, no phenol red 31053044 Life Technologies 
(Gibco), USA 
RPMI 1640 with phenol red 21875091 Life Technologies 
(Gibco), USA 
DMEM/F12 no phenol red 21041033 Life Technologies 
(Gibco), USA 
B-27 Supplement (50X), minus 
vitamin A-10 mL 
12587010 Life Technologies, USA 
EGF Recombinant Human Protein PHG0315 Life Technologies, USA 
bFGF Recombinant Human Protein 13256029 Life Technologies, USA 
PBS 10010056 Thermo Fisher 
Scientific, USA 
PenStrep 15140122 Thermo Fisher 
Scientific, USA 
Serum-free Opti-MEM I Reduced 
Serum Media 
31985062 Thermo Fisher 
Scientific, USA 
Endopan 3 kit P04-0010K Pan-Biotech, Germany 
Trypsin (0.05%) 25300062 Life Technologies by 
Thermo Fisher 
Scientific, USA 
FBS 10500064 Life Technologies 
 
2.8 Buffers and solution 
Name Composition 
1×TBST (1L) 100ml 10×TBS, 1ml Tween 20 
10%APS 1g APS, 10ml H2O 
10%SDS 0.5g SDS, 50ml H2O 
10×TBS (1L) 31.52g Tris HCl, 80g NaCl, adjust pH to 7.6 
5% Milk 10g fat skim milk powder, 200ml 1×TBST 
Anode I buffer (1L) 36.4g Tris base, 200ml Methanol 
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Anode II buffer (1L) 3g Tris base, 200ml Methanol 
Cathode buffer (1L) 3g Tris base, 5.2g 6-aminocaproic acid, 200ml methanol 
Lysis buffer (10ml) 
NP-40(20%) 500µl, Na-cholate (10%) 1000µl, 
ASB-14 (5%) 1000µl, 12-Maltoside (2.5%) 1000µl, 
Glycerol (99%) 2000µl, Bicine (0.5M, pH 8.5) 1000µl 
NaCl (1.50M) 1000µl, EDTA.2Na (0.02M) 1000µl 
PMSF (200mM) 50µl, Pro&Phosph inbihitor 100µl 
Benzonase 4µl, dH2O 1346µl 
1×PBST (1L) 
8g NaCl, 0.2g KCl, 1.44g NaHPO4, 0.24g KH2PO4 
1ml Tween 20, adjust pH to 7.4 
Sammel Buffer 
47.28g Tris HCl in 200ml dH2O,  
adjust pH to 6.6 with NaOH 
10×TBE Buffer (1L) 108g Tris, 55g Boric acid, 40 ml 0.5M Na2EDTA, pH=8 
Trenn Buffer (200ml) 36.33g Tris.Base, adjust pH to 8.8 with HCL 
Western blot wet 
transfer buffer 
3g Tris Base, 14.4g Glycine, 1gSDS,  
800ml H2O, 200ml methanol 
LB-Medium (1 L) 
10 g Tryptone/Pepton, 5 g yeast extract, 5 g NaCl, pH 
7.2 
LB-Agar LB-Medium + 1.5% (w/v) Agar 
PBS 10× (1 L) 
80g NaCl, 2g KCl, 26.8g Na2HPO4, 2.4g KH2PO4, pH 
7.4 
TBE 10× (1 L) 108 g Tris, 55 g Boric acid, 40 ml 0.5 M Na2EDTA, pH 8 
TBS 10× (1 L) 50 mM Tris, 150 mM NaCl with HCl, pH 7.5 
1M HEPES-KOH 
pH 7.5 (1 L) 
238.30 g HEPES. adjust pH to 7.5 with KOH 
1 M Tris-HCl  
pH 6-8 (100ml) 
12.1 g tris base, adjust pH with HCl 
0.5 M EDTA pH 8.0 (1L) 
186.1 g Na2EDTA.2H2O, adjust pH to 8.0 with NaOH 
(~20 g of NaOH pellets). EDTA dissolve at pH 8.0.  
FACS sorting buffer PBS with 2% FBS 
Blocking buffer 
(immune-assay) 
1x PBS, 0.05 % Tween, 2 % BSA 
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Blocking buffer (PDI) 
25mM HEPES-NaOH (pH=7.9), 50mM glutamate 
potassium, 8mM magnesium acetate, 0.1 % Triton X-
100, 10 % glycerol, 1xHaltTM Protease & Phosphatase 
inhibitor, 1mM Dithiothreitol, 4μg Herring sperm DNA, 
2 % BSA 
Washing buffer (PDI) 
25mM HEPES-NaOH (pH=7.9), 50mM glutamate 
potassium, 8mM magnesium acetate, 0.1 % Triton X-
100, 10 % glycerol 
Hybridization buffer 
(PDI) 
125nM methylated and unmethylated DNA fragments 
respectively in 1 ml blocking buffer (PDI) 
 
2.9 Software and packages 
Software Company/Websites 
GO Enrichment Analysis http://geneontology.org 
GenePix Pro.6.0 Molecular devices, USA 
R version 3.4.4 
Package ggplot2 version 2.2.1 
GEPIA http://gepia.cancer-pku.cn 
Image J software National Institutes of Health 
MultAlin Corpet, 1988 
NEB-Tm calculator https://tmcalculator.neb.com/#!/main 
OpenCFU 3.8 BETA software open-source software developed by 
Quentin Geissmann 
FlowJo Ashland, Oregon-based FlowJo LLC, USA 
Ingenuity pathway analysis QIAGEN Bioinformatics, Germany 
Gene set enrichment analysis Broad institute, USA 
DBTSS https://dbtss.hgc.jp 
  
BiQ Analyzer Max Planck Institut Informatik, DE 
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2.10 Vectors, siRNA, primer 
Name Company Note 
Control scramble siRNA Santa Cruz, USA - 
MISSION Pre-designed siRNA -
2 OD (Anti-NFATc1) 
Sigma, USA - 
pL-CRISPR.EFS.GFP Gift from Prof. Dr. med. 
Carstern Müller-
Tidow’s group 
System Biosciences, 
USA 
VSVG Gift from Prof. Dr. med. 
Carstern Müller-
Tidow’s group 
- 
pLP1 Gift from Prof. Dr. med. 
Carstern Müller-
Tidow’s group 
- 
pLP2 Gift from Prof. Dr. med. 
Carstern Müller-
Tidow’s group 
- 
pCDH Gift from Prof. Dr. med. 
Carstern Müller-
Tidow’s group  
System Biosciences, 
USA, CD513B-
1_10042017 
q-PCR primer Qiagen, Germany HPRT1, GAPDH, 
ALDH1A3, MKNK2, 
SLC7A5 
Primer Biomers.net GmbH, 
Germany 
- 
pCpGL Rehli’s lab  
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3 Methods 
3.1. The mRNA and methylation profiling of patients and cell 
lines 
3.1.1. The mRNA profiling of patients and cell lines 
Expression profiling data of patients was available from previous studies [118]. In 
summary, the total RNA from individual samples with RNA integrity number of at least 
seven was analyzed on the Sentrix Human-6v3 Whole Genome Expression 
BeadChips (Sentrix Human WG-6; Illumina). The raw data was quantile normalized 
and log2 transformed. Differential expression analysis was performed using the 
LIMMA package by pairwise comparisons of the groups. The resulting p-values were 
adjusted for multiple testing using Benjamini-Hochberg's false discovery rate (FDR) 
method; features with FDR P value < 0.01 and absolute log2-fold change (log2FC)>0.5 
were considered significant. 
 
Additionally, Panc1, HPDE were cultured as written in section.3.3.3. RNA and DNA 
were extracted simultaneously using AllPrep DNA/RNA Mini Kit (DNA). For the mRNA 
profiling, RNA was analyzed on Illumina HT12 (Human Sentrix-12 BeadChip). The raw 
data was quantile normalized and log2 transformed. HPDE was considered as the 
healthy control cell line. The fold change was simply calculated by comparing the 
mRNA expression level of two different cell lines.  
 
3.1.2. The methylation profiling of patients and cell lines 
Genome-wide DNA methylation analysis of patients was performed using the Illumina 
Infinium 450k DNA methylation platform (Illumina) on 26 PDAC tissues, 24 normal 
pancreases, 12 chronic pancreatitis (CPs), and 2 cell lines which mentioned in section 
3.1.1. The analysis procedure followed the manufacturer’s standard workflow. The 
resulting raw data files were preprocessed using default RnBeads workflow [119]. 
Briefly, Quality control, probe filtering, background correction, and batch effect 
correction were performed as recommended. The preprocessed data was normalized 
by SWAN method. Differential methylation analysis was performed by limma-based 
method.  
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For the methylation data of tissue, after quality control assessments, differentially 
methylated probes were selected from the list of Infinium probes whose FDR-adjusted 
p ≤ 0.01 and absolute methylation difference ≥ 0.15. Concerning the definition of 
promoter region, it’s defined as the regions 1.5 kb up-stream and 0.5 kb downstream 
of transcription start sites. Differentially methylated promoters were selected by setting 
the criteria (FDR-adjusted p ≤ 0.05, absolute methylation difference ≥ 0.1). For the 
analysis of cell line data, the fold change of beta value was simply calculated by 
comparing the mRNA expression level of two different cell lines.  
 
3.1.3. The integration analysis 
In order to investigate the association between expression and methylation, 
methylation and expression data of tissue was integrated. Two strategies are used, 
one was based on the probes, the other was based on the average beta value in the 
promoter region. Firstly, significantly differentially methylated probes or promoters 
were selected followed by the selection of significantly differentially expressed genes. 
Afterward, the methylation data of each probe or promoter corresponding with one 
gene was integrated with the expression data of the same gene. As such, the 
expression data and methylation data of tissue was integrated.  
 
3.1.4. Gene ontology enrichment analysis 
The gene ontology enrichment analysis [120-122] was performed by using 
PANTHER14.1 according to the manual of GO Enrichment Analysis. The reference 
list was set to ‘humo sapiens’; ‘GO biological process complete’ was chosen to be the 
annotation data set; the test type was Fisher's exact and the correction method was 
to caculate False Discovery Rate. 
 
3.2. The identification of methylation-dependent transcription 
factor 
3.2.1. Template Generation for Protein Microarray Production  
DNA templates for on-chip protein expression were constructed by 2-step PCR 
reaction. Template DNA for PCR was obtained from a transcription factor library which 
was kindly provided by Professor Jussi Taipale. The open reading frames (ORFs) of 
667 DBD of transcription factors were constructed in gateway system-PDNOR223 
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vector. In order to generate DNA templates (5’end to 3’end) consisting of T7 promoter, 
untranslated region (UTR), ribosome binding sites (RBS), 6His, ORF, V5, stop codons 
and T7 terminator, following steps were performed. Briefly, the bacteria with the clone 
was inoculated in bacterial culture with 150µl 2YT which contained 50µg/mL 
spectinomycin in a 96 plate well for each clone in the transcription factor library. The 
plate was shaken at 37℃ at 150rpm overnight. The next day, the plate was centrifuged 
at 4000rpm for 30mins at room temperature. After the centrifugation, the supernatant 
was discarded, and the pellet was resuspended with 100µl sterilized water. Afterward, 
the plate was incubated in an oven at 75℃ for 20minutes, and the plate was 
centrifuged at 4000rpm for 30mins at room temperature. In the end, the supernatant 
was transferred into a new 96 plate, and this was the templates ready for the 
downstream 2-step PCR amplification. The PCR reaction system are listed as below. 
When cycling was done following the manufacturer’s instructions, 5μl of PCR products 
was checked on 1.2% agarose gels. 
 
Table 3.1 1st PCR system 
1st PCR 
Component 
Final 
Concentration 
Volume 
(µl) 
10xBuffer with MgCl2(25mM) 1xBuffer 14 
dNTP (10mM） 200µM 2 
M13 Primer for (100µM) 400nM 0.4 
M13 Primer rev (100µM) 400nM 0.4 
Taq (5 units/µl) 1U 0.2 
Nuclease free water  73 
Template (from boiled E. coli)  10 
In total  100 
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Table 3.2  2nd PCR system 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2. In Situ Cell-Free Protein Expression  
The high-throughput spotting technique was used for on-chip protein expression. S30 
T7 High yield protein expression system was used for the in vitro expression. 
Expression constructs were transferred to 384 plates. The plate was briefly spun down. 
Approximately 7nl of template (2 droplets) was spotted by using a non-contact Nano 
plotter 2 onto the epoxy coated slides surface followed by 28nl (8 droplets) of the cell-
free expression. Each slide was incubated in a metal hybridization chamber which 
were filled into 30µl nuclease-free water in both ends. Afterward, the hybridization 
chamber was placed in a plastic box which was filled with wet tissue paper to keep 
certain humidity. The whole box was incubated in a ventilated oven at 30℃ for 2 hours 
followed by 37℃ incubation overnight. Slides were removed from the metal 
hybridization chambers and stored at –20°C for at least 24 hours before use. 
 
3.2.3. Detection of Expressed Proteins  
To determine successful expression of TFs, the spotted epoxy slide was firstly blocked 
with 2 ml blocking buffer for 1h on an orbital shaker at 100 rpm. Subsequently, it was 
2nd PCR 
Component Final 
Concentration 
Volume  
(µl) 
10xBuffer with MgCl2 
(25mM) 
1xBuffer 14 
dNTP (10mM） 200µM 2 
TF Primer for (100µM) 400nM 0.4 
TF Primer rev (100µM) 400nM 0.4 
Taq (5 units/µl) 5U 1 
Betain (5M) 0.5M 10 
Nuclease free water  62.2 
Template (From 1st PCR)  10 
In total  100 
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washed twice with 2 ml PBST-0.05 % Tween 20 for 5 mins at 200 rpm. Next, the epoxy 
slide was incubated for 1 h with 1:1000 dilution of Alexa Fluorâ 647 conjugated anti-
HisTM antibody and Cy3TM conjugated anti-V5- antibody in 1 ml blocking buffer at 100 
rpm. Before three times rinsing with VE-H2O, the slide was washed thrice with 2 mL 
PBST for 7 min at 200 rpm. Subsequently, the slide was centrifuged at 1000 rpm for 
5 min to remove all liquids. In the end, the scan was performed using the Tecan power 
scanner V1.2 with a resolution of 10μm, laser intensity of 75 %, channel one 
wavelength of 580/30 nm and channel two wavelength of 676/37 nm. The images were 
analyzed with GenePix Pro.6.0. The median fluorescence intensities (MFI) was 
extracted for the analysis. The value of mean MFI of negative controls plus 4 standard 
deviation was set as the threshold for the positive expression. 
 
3.2.4. Protein-DNA interaction analysis 
When the protein microarray is ready, the slides were used for the protein-DNA 
interaction (PDI) assay. Firstly, the annealing of methylated and unmethylated Cy-
tagged Twist1 promoter oligonucleotides was performed. The unmethylated forward 
strand was conjugated with Cy3, while the methylated forward strand was conjugated 
with Cy5. 20μM of complementary forward and reverse strands were heated in 1x 
NEB buffer 2 at 95 ◦C for 5 min using a LifeECO thermal cycler. Afterwards, the sample 
was cooled down to 4 ◦C at a rate of 1◦C per second to enable annealing of 
complementary strands. The annealed oligos were purified by following the 
manufacturer’s protocol of Illustra MicroSpin G-25 Columns. Subsequently, the 
concentration of the purified oligonucleotides was measured using the Nanodrop ND-
1000. 
 
To test interactions between TFs and methylated/unmethylated fragments, a 
competitive protein-DNA interaction assay was performed. Firstly, the slide was 
blocked with 2 ml blocking buffer for 1h on an orbital shaker at 100 rpm. Next, it was 
washed twice with 2mL washing buffer for 5 min at 200 rpm on an orbital shaker. 1 ml 
hybridization buffer was added and incubated overnight at 4 ◦C on an orbital shaker. 
Next, the slide was washed thrice with 2 ml washing buffer for 5 min at 200 rpm on an 
orbital shaker. Afterward, the slide was rinsed with VE-H2O thrice followed by 
centrifugation at 1000 rpm for 5 min to remove all liquids. The scan was performed by 
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using the Tecan Power Scanner V1.2 with a resolution of 10μm, laser intensity of 75 %, 
channel one wavelength of 580/30 nm and channel two wavelength of 676/37 nm. The 
images were analyzed with GenePix Pro.6.0. 
 
3.3. The Expression pattern of NFAT family in PDAC tissue and 
related cell lines 
3.3.1. in-house data analysis 
The mRNA profiling of the tissue samples was from previous study as written in 
section3.1.1 {Bauer, #582}. In summary, there are 41 healthy tissue sample, 59 
chronic pancreatitis and 195 PDAC. The expression of NFATc1 was analyzed with the 
statistical analysis of one-way ANOVA test. Next, the result was visualized in a Box-
and-Whisker Plot by using R and the package of ggplot2.  
 
3.3.2. online data analysis 
In order to validate the expression of NFATc1 in an independent dataset, TCGA and 
GTEx data were used for validation. The online tool, GEPIA [123] was applied. 
Boxplots of NFATc1 were generated by using “Expression on Box Plots” module, 
PAAD dataset and Log Scale. Moreover, TCGA normal and GTEx data were used as 
normal control. Stage plot of NFATc1 was generated by using “Pathological Stage Plot” 
module, PAAD dataset and Log Scale.  
 
3.3.3. Cell culture 
Panc-1, BxPC3, Miapaca2, Aspc1, Capan1, Suit2 and HPDE used in this study were 
purchased from ATCC and authenticated by DKFZ internal service. All cells were 
regularly checked for mycoplasma contamination. The detailed information of each 
cell line was listed as below. When necessary, all the complete culture medium was 
supplemented with 1% pen-strep, 1% L-glutamine, and 10% FBS with normal cell 
culture procedures, if not specified with *. In terms of the normal cell culture prociduals, 
the cells were split when the confluency is around 80 %. To do so, the old medium 
was discarded, and cells were washed with PBS. Next, the cells were incubated with 
trypsin in the cell culture incubator. Afterward, the trypsinization was stopped by 
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adding complete media when the cells were detached from the bottom of the flask. To 
determine the cell density, Vi Cell XR cell counter was used.  
 
Table 3.3 Cell culture list 
Cell line Tumor 
Type 
Disease Media 
Panc1 Primary 
tumor 
Epithelioid 
carcinoma 
IMDM 
BxPc3 Primary 
tumor 
Adenocarcinoma IMDM 
Miapaca2 Primary 
tumor 
Carcinoma DMEM 
Aspc1 Ascites 
(metastatic) 
Adenocarcinoma RPMI 
Capan1 Liver 
metastasis 
Adenocarcinoma IMDM 
Suit2 Liver 
metastasis 
Carcinoma DMEM 
HPDE* None None Keratinocyte-SFM 
Medium kit 
 
3.3.4. mRNA expression level analysis of cell lines 
To investigate the mRNA expression level of NFATc1 in pancreatic cancer cell lines, 
RNA from Panc-1, Miapaca2, and Aspc1 cell lines was isolated by using the AllPrep 
DNA/RNA kit. The isolation was performed according to the protocol of the kit. 
Additionally, the quality of the RNA was checked by using 1 % agarose gel. RNA 
concentration was measured with Nanodrop and 500 ng of RNA was used for the 
reverse transcription. 
 
cDNA synthesis was performed via ProtoScript® First Strand cDNA Synthesis kit, 
following manufacturer’s instructions. After synthesis, the cDNA was stored at -20 °C 
for qPCR. 
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To perform a quantitative real-time PCR reaction, Fast SYBRTM Green and 
Lightcycler480 were used. Three technical replicates were prepared. The primer, 
reaction system, and program used for real-time PCR were listed as below. Afterward, 
the data was analyzed by ΔΔCt method.  
Table 3.4 Reaction system used for Realtime PCR 
Gene Component 1× run (μl) 
 
 
HPRT1 
NFATc1 
cDNA 1 
Primer (10μM) 1 
SYBR Green Master Mix 
(2×) 
5 
Nuclease-free water 3 
Total Volume 10 
 
 
Table 3.5 Program used for real time PCR 
Step Temperature 
(°C) 
Duration Cycles 
Polymerase 
activation 
95 20s Hold 
Denature 95 3s  
       40 Anneal/Extend 60 30s 
 
3.3.5. Protein expression level analysis of cell lines 
For protein isolation, Panc-1, BxPC3, Miapaca2, Aspc1, Capan1, Suit2, and HPDE 
cells in culture were washed twice with ice-cold PBS and lysed with lysis buffer. To 
prepare for the lysis buffer, 10ml RIPA Lysis and extraction buffer was supplemented 
with 100μl of 100 X HaltTM Protease and Phosphatase Inhibitor Cocktail, 
phenylmethylsulfonylfluoride (PMSF) and 4μl Benzonase Nuclease. 300μl of RIPA 
buffer was added into each well of 6 well plates, and the samples were kept on ice for 
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5 minutes with occasionally swirling. The collected lysate was centrifuged at 4 °C for 
15 minutes at 14,000 g using Centrifuge 2K15. The supernatant containing the 
solubilized proteins was stored at -20 °C for further analysis. Afterward, the 
concentration of the protein was determined by following the instruction of the PierceTM 
BCA Protein Assay kit. The Infinite® M200 plate reader was used for the measurement 
at an absorbance of 562nm. 
 
For western blotting analysis, 10-20μg samples mixed with 25 μl 4X laemlli sample 
buffer were denatured for 5 minutes at 95 °C in a heating block and loaded onto 10% 
SDS-PAGE gels. Samples were stacked for 30 min at 75 V and separated for one 
hour at 135 V in the running buffer with the microcomputer electrophoresis power 
supply. The semi-dry method was used to transfer the samples from the SDS-PAGE 
gel to a nitrocellulose membrane. The Trans-Blot® TurboTM was used to transfer for 30 
minutes at 25V (standard transfer program). Then, membranes were blocked in 5% 
non-fat milk in TBST-0.05% Tween 20 for 1h at room temperature, and the blocking 
was followed by washing with TBST and incubation with first antibody (anti-NFATc1, 
anti-GAPDH) overnight at 4°C on a benchtop rocker. Immunodetections were 
performed with the corresponding secondary antibodies (HRP Horse Anti-Mouse IgG 
Antibody). Enhanced chemiluminescence (ECL) reagents and Image Quant 
Luminescent Image Analyzer LAS-4000 mini was used for visualization. The 
densitometric analysis was done by using ImageJ software. 
 
3.4. The Functional study of NFATc1 in pancreatic cancer cell 
line 
3.4.1. The knock-down of NFATc1 by siRNA transfection in cell lines 
Cells were seeded in a 6-well plate 24 hours before the transfection to get a confluency 
of at least 50 % the next day. Complete medium without Pen-Strep was used for the 
siRNA transfection. According to manufacturer’s protocol of Lipofectamine® 2000 
Transfection Reagent for 6-well transfection, Serum-free Opti-MEM I Reduced Serum 
Media was used to prepare the complex for transfection. Three different 
concentrations of siRNA (33.3 nM, 66.6 nM, 99.9 nM) were tested for all pancreatic 
cancer cell lines, and the knockdown effect was compared with the effect of control 
scramble siRNA. Medium was changed to complete medium 7 hours after transfection, 
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In the end, cells were harvested 24 hours post transfection for real time quantitative 
PCR and 48 hours post transfection for western blot.  
 
3.4.2. The knock-out of NFATc1 by CRISPR/Cas9 gRNA transfection 
in cell lines 
Vector cloning: CRISPR plasmid pL-CRISPR.EFS.GFP with scramble gRNA or gRNA 
specifically targeting NFATc1 was generated. Firstly, 1μl 100μM Single Guide RNA 
(sgRNA) oligos were phosphorylated using 0.5μl of the T4 polynucleotide kinase with 
1μl of T4 DNA Ligase buffer, and the reaction was filled up to 10μl with nuclease free 
water followed by the incubation for 45 minutes at 37 °C and 2.5 minutes at 95 °C in 
a thermocycler. Afterward, it was cooled down to 22°C at a speed of 0.1°C per second. 
Secondly, 3μg of the vector pL-CRISPR.EFS.GFP was linearized using 3μl enzyme 
BsmbI in a 50μl reaction system following the manufacturer’s instruction. The mixture 
was loaded on a 1% agarose gel after the incubation and the linearized vector was 
extracted by using NucleoTrap® kit according to the manufacturer’s instruction. 
Subsequently, the annealed and phosphorylated oligos were ligated with the purified 
linearized plasmid. To do so, 30-50 ng of the vector was mixed with 1μl of the 1:500 
diluted oligo mix, 0.5μl QuickLigase enzyme and appropriate 2 X QuickLigase buffer 
to an overall volume of 10μl. The reaction was incubated for 5 minutes at room 
temperature.  
 
Afterward, 2μl ligation product was used to transform 50μl of Stbl3 chemically 
competent E. coli. The bacteria were plated on pre-warmed agar plates containing 0.1% 
Ampicillin. After overnight incubation, positive clones were confirmed by colony PCR 
and inoculated in 5 mL of LB-media supplemented with 0.1 % of Ampicillin. The 
plasmid was extracted by using Spin Miniprep kit after another overnight, and the 
isolated constructs were sent for sequencing (eurofins genomics, Germany, 
Ebersberg) with the commonly used primer LKO.1 5'. Using the free-source program 
MultAlin, the sequenced DNA was scanned for the integrated sgRNA. 
 
Lenti-virus production: 107 HEK cells were plated in 150cm petri dish 1 day before 
packing the virus. On the day of virus packing, 13ml medium was refreshed one hour 
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before transfection. Firstly, 48μl TurboFect was incubated with 1.5ml opti-MEM for 5 
minutes, 10.4μg plasmid with insertion of interest was mixed with 4μg VSVG, 7.2μg 
pLP1, 2.4μg pLP2 and 1.5ml opti-MEM. The TurboFect mixture was added into the 
plasmid mixture followed by gently pipetting up and down and incubation of 15 minutes 
at room temperature. Next, this 3ml mixture was added into 15cm petri dish in a droplet 
manner, and the medium was refreshed 5 hours later after the transfection. The 
supernatant was harvested 2 days and 3 days respectively after the transfection, 
filtered by 0.45μm filter, ultraconcentrated collectively at 20000rpm at 4 degree for 2 
hours, and discarded. The virus pellet was resuspended in 150μl cold PBS. 
Alternatively, the supernatant can also be concentrated by Vivaspin 20 centrifugal 
concentrator (MWCO 30kDa) at 4 degree. In the end, the virus was aliquoted into 20μl 
per tube.  
 
Transduction: For transduction, 2-3 x 105 cells were seeded per well in a 6-well cell 
culture plate. In each well, 20μl of concentrated virus mixed with 200μl of culture 
medium was added in a droplet manner in a final volume of 2ml culture medium with 
polybrene in a final concentration of 10μg/ml. The cells were incubated with the virus 
overnight and washed three times with PBS the next day followed by refreshing culture 
medium.  
 
FACS sorting: 72 hours after the transduction, the cells were used for the FACS sorting. 
Every sample was pelleted and resuspended with 250μl of sorting buffer. Afterward, it 
was filtered by using test tube with cell strainer snap cap. Live cells with GFP positive 
signal were sorted by BD FACSAriaTM III machine and collected in 1 ml culture medium, 
the service was provided by DKFZ core facility. In the end, the sorted cells were plated 
into a cell culture plate. After 24 hours, the culture media was refreshed. 
 
Knockout validation: The sorted cells were harvested until the cells reached the 
confluency of 80% in 6-well plate. DNA and RNA were isolated simultaneously by 
using AllPrep DNA/RNA kit. Protein was isolated as previously described. For the 
knockout-validation at DNA level, the sgRNA targeting region was amplified by 
touchdown PCR. The reagent system and PCR running program is listed as below. 
After the amplification, the PCR product was purified by using PureLink® PCR 
Purification Kit. The purified PCR product was sent for sequencing with the forward 
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PCR primer. For the knockout-validation at protein level, the Western Blot (WB) 
experiment was performed. Anti-NFATc1 antibody and anti-GAPDH antibody were 
used for the specific detection of the target protein expression.  
                                   
Table 3.6 Reaction system used for PCR 
Sample Component 1× run (μl) 
 
 
pL-
CRISPR.E
FS.GFP 
Sg1-sg4 
10x buffer 2 
Prisg1/2_For or Prisg3_For 
primer (10μM) 
0.8 
Prisg1/2_rev or Prisg3_rev 
primer (10μM) 
0.8 
dNTP(10mM) 0.4 
Hot start Taq polymerase 
(5U/ μl) 
0.2 
Template 1 
Nuclease-free water Up to 20 
 
Table 3.7 Program Used for Touchdown PCR 
Step Temperature 
(°C) 
Duration Cycles 
Polymerase 
activation 
95 15min Hold 
Denature 94 30 s  
20 Anneal/Extend Tm+5 30 s 
Elongation 72 30 s 
Denature 94 30 s  
20 Anneal/Extend Tm-5 30 s 
Elongation 72 30 s 
Final Elongation 72 5min Hold 
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3.4.3. The overexpression of NFATc1 in cell lines 
In order to generate the stable NFATc1-overexpression cell lines, cloning, virus 
production, transduction, FACS sorting and validation were performed sequentially. 
Firstly, NFATc1 clone (CloneID: 111759121) in pENTR223 vector was ordered from 
DKFZ core facility. The open reading frame was amplified by Q5â reaction system with 
the NFATc1-OE forward primer and NFATc1-OE reverse primer. Touchdown PCR 
program was performed. Then, the PCR product was purified by using PureLink® PCR 
purification kit according to the manufacturer’s instructions. The overexpression vector 
pCDH was digested by EcoRI and BamHI enzymes. Subsequently, the digested 
vector was purified by gel extraction accordingly. Afterward, In-Fusionâ HD cloning 
reactions was applied according to the manufacturer’s instructions. The positive clone 
was verified by sanger sequencing. Subsequently, virus production, transduction, 
FACS sorting and validation of protein level were performed as previously written in 
3.4.2. 
    
3.4.4. Proliferation assay 
Resazurin assay was performed to check the proliferation effect of NFATc1 on Panc1 
and Miapaca2. Briefly, the transfection of NFATc1-specific siRNA and scramble RNA 
was performed on Panc1 and Miapaca2 as previously written in 3.4.1. The 
experiments were conducted in a 48-well plate and 3 biological replicates were 
prepared respectively for experimental and control group. At the timepoint of 24, 48, 
and 72 hours after the siRNA knockdown, the samples were incubated with 200μl 
culture medium containing 20μg/ml resazurin for 1 hour in the cell culture incubator. 
In the end, the fluorescent resorufin was measured by using the plate reader FLUOstar 
Galaxy at excitation wavelength of 544 nm and emission wavelength of 590 nm. 
 
3.4.5. Migration assay 
Sarstedt TC inserts with a pore size of 8µm for 24-well plates were used to perform 
the migration assay. Firstly, the transfection of NFATc1-specific siRNA and scramble 
RNA was performed on Panc1 and Miapaca2 as previously written in 3.4.1. The cells 
were harvested 24 hours after the knockdown. Next, 2000 cells in 0.2ml FBS-free 
medium was added to each insert. Then, 0.5 ml chemoattractant (10% FBS complete 
culture medium) was added to the bottom of 24 well plates. 3 biological replicates were 
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prepared for experimental and control group respectively. Afterward, the cell invasion 
chambers were incubated in cell culture incubator for 24 hours followed by crystal 
violet staining. Briefly, the medium from the inserts was aspirated firstly. Prior to the 
staining, non-migrated cells were removed from the inserts manually by gently 
swabbing the inside part of each insert with cotton swabs. Next, the inserts were 
washed with ice-cold PBS and fixed with ice-cold 100% methanol for 10minutes. After 
the fixation, the methanol was aspirated from the inserts and the inserts were covered 
by 0.5% crystal violet solution in 25% methanol for 10minutes. The inserts were 
washed in VE-water several times until the dye stops coming off followed by drying at 
room temperature. In the end, Zeiss Axio Examiner Z1 was used for taking pictures 
for each replicate. Under microscope, 5 different fields of view were observed, and 
images were captured. ImageJ was used to measure the area of crystal violet staining.  
 
3.4.6. Colony assay 
The sorted transduced Panc1 and Miapaca2 cells as previously written in 3.4.2 and 
3.4.3 were used for colony assay after 5 days culture. Briefly, 3 biological replicates 
were prepared for the experimental and control group respectively. Initially, for the first 
layer, 10ml autoclaved 2 % soft SeaKem® GTG® Agarose in PBS was mixed with 30 
ml pre-warmed culture medium to prepare 0.5% agar. 2 ml 0.5% agar was then plated 
in each well of 6-well plates. The plate was incubated at room temperature for at least 
20 minutes until the agar became solid. Afterward, 3.2 ml pre-warmed culture medium, 
0.4 ml FBS and 0.4ml 2% agar were mixed together to prepare 0.05% agar which was 
incubated at 37°C. Meanwhile, the sorted cells were harvested and counted. Then, 
3300 sorted cells were resuspended in 1ml 0.05% agar and the suspension was 
quickly added on the top of the first layer of 0.5% agar. After the incubation of 
20minutes at room temperature, 1ml complete culture medium was added on the top 
of agar. In the end, the plates were incubated for 3 weeks in the Galaxy 170 S 
incubator. After 3-weeks culture, 0.5 ml of 0.005% Crystal Violet was incubated in 
each well for more than 1 hour on an orbital shaker. Next, each well was washed with 
PBS until the background is clear. Images were taken by the camera. To count 
colonies, OpenCFU 3.8 BETA software was used for the image analysis. For the 
setting of the software, the radius for a colony was set to 5 for Miacapa2 and to 7 for 
Panc1 since the size of cells derived from diverse cell lines was different.  
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3.4.7. Apoptosis assay 
Firstly, for Panc1 and Miapaca2, the transfection of NFATc1-specific siRNA and 
scramble RNA was performed as previously written in 3.4.1. The cells including the 
floating apoptotic cells were harvested and washed gently with serum-containing 
culture medium once 48 hours after the knockdown. 3 biological replicates were 
prepared for experimental and control group respectively. For each replicate, 
approximately, 106 cells/ml cells were resuspended in 200μl 1x Annexin V binding 
buffer containing 2μl Annexin V-Cy5 and 1μg/ml PI. Next, the samples were kept on 
ice and must be analyzed within an hour to avoid false positive measurements. Before 
the analysis of FACS, negative control cells, GFP cells, Non-GFP cells with PI staining 
and Non-GFP cells with Annexin V staining were used for compensation setting. In 
terms of FACs analysis, 3 lasers including GFP, PI, Cy5 were used. The voltage was 
set accordingly, and the population of interest was clear visible by making adjustment 
of FSC/ SSC. Finally, the results were analyzed by FlowJo software.  
  
3.5. The analysis of NFATc1 related pathway 
3.5.1. mRNA profiling of knock-down cell lines 
Firstly, for Panc1, Miapaca2, Suit2, the transfection of NFATc1-specific siRNA and 
scramble RNA was performed as previously written in 3.4.1. Total RNA was isolated 
using TRIzolTM Reagent 40 hours after transfection according to the manufacture’s 
protocol. 500 ng RNA from each cell line transfected with NFATc1-specific siRNA or 
control scramble RNA was sent for Illumina HT12 (Human Sentrix-12 BeadChip) gene 
expression profiling. DKFZ genomics and proteomics core facility performed this 
service. Briefly, the labeled cRNA was hybridized with over 47,000 probes conjugated 
to beads on the array at 58 °C for 17 hours. Afterward, the microarray was scanned 
by the Illumina iScan array scanner according to the standard Illumina scanning 
protocol. The intensity value of each probe was measured accordingly. The bead-level 
data analysis of the gene expression microarray was done with R by core Facility. To 
do so, after the outlier removal, the quantile normalization was performed. Studentís 
t-test was used for the significance test. Additionally, for each group, the average 
expression value was calculated as mean of the measured expressions of beads 
together with the standard deviation of the beads, and p-values was calculated using 
averaged expression values for each sample in the group. Furthermore, Benjamini-
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Hochberg correction was applied to p-values of all probe IDs on the chip for the 
differential expression analysis. The averaged expression level of the treated group 
divided by the control group was the fold change (FC). In the end, the visualization of 
the data was performed by R. 
 
3.5.2. Data analysis 
In order to identify enriched gene sets, involved pathways, and influenced function 
upon the knockdown of NFATc1. Gene set enrichment analysis was performed. Firstly, 
the gene set enrichment analysis was done by using Broad Institute algorithm 
following the standard protocol. The normalized transcriptional profiling microarray 
data of all 6 samples was used for the input of this analysis. Gene sets, whose 
Normalized Enrichment Score (NES) above 1, p-value below 0.05, and false discovery 
rate (FDR) Q-value below 0.25 were considered as significant enriched gene sets.  
 
3.6. Candidate validation  
3.6.1. Validation of candidates via q-PCR 
Candidate selection: RNA samples from Panc1, Miapaca2, and AsPc1 were sent for 
gene expression profiling as previously written in section 3.5.1, in which siRNA-
mediated knockdown of NFATc1 was performed. The top 30 genes downregulated 
candidates were taken for further considerations. Afterward, genes showing 
upregulation in PDAC group compared with healthy group were kept, other genes 
were removed from the list of candidates. Then, the promoter sequence (-
2000bp/+500bp) of all these genes were extracted from DBTSS [124], and the 
promoter sequence was analyzed by MEME-FIMO [125]. The motif of NFATc1 [23] 
was used as input for the analysis. When the binding site of NFATc1 in the promoter 
region was predicted (P<0.01), the methylation level of the binding site was analyzed 
by integration of 450k array data from tissue and cell line including Panc1 and HPDE. 
 
Validation via q-PCR: The NFATc1-overexpression, -knockdown, -knockout cell 
models established as previously written in section 3.4.1, 3.4.2 and 3.4.3 were 
employed for the candidate validation. After the cells were harvested, RNA isolation, 
cDNA synthesis and quantitative real-time PCR reaction were performed as written in 
3.3.4. HPRT1 was used as a housekeeping gene for all the samples. Primer NFATc1 
Methods 
 60 
 
was firstly recruited to verify the establishment of cell models. Afterward, Primer 
ALDH1A3, SLC7A5, and MKNK2 were used to detect the mRNA regulation of the 
selected candidates upon the overexpression, knockdown and knockout of NFATc1. 
The q-PCR result was analyzed via DDCt method. 
 
3.6.2. Validation of candidates via methylation specific PCR 
In-house data analysis: For the validation at expression level, the expression of the 
candidate genes was checked in the mRNA profiling of cell lines and tissues. For the 
validation at methylation level, the beta value of candidate genes was investigated 
from the 450K array data of cell lines and tissues.  
 
Methylation-specific PCR (MSP): The DNA was isolated from Panc1 and Miapaca2 by 
using the AllPrep DNA/RNA Mini Kit according to manufacturer’s recommendations. 
For each cell sample, 1μg of isolated DNA was used for bisulfite conversion with the 
EpiTect Bisulfite Kit according to manufacturer’s recommendations, and the 
concentration of bisulfite converted DNA was measured by Nanodrop. Next, MSP was 
performed as written below in the table 3.8, 3.9. Briefly, 2.5ng of each template was 
amplified using methylation-specific primer pair. Methylated Bisulfite Converted 
control DNA (MBC) and Unmethylated, Bisulfite Converted control DNA (UBC) from 
the EpiTect PCR Control DNA Set were used to validate the specificity of the primers. 
The size of the expected products was 100bp for ALDH1A3. To visualize the result, 
5μl per sample was applied to a 3 % agarose gel and separated at 500 mA and 130 
V for 0.7 h. 
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Table 3.8 Reaction system used for MSP 
Sample Component 1× run (μl) 
 
 
Bisulfite 
converted 
Panc1, 
Miapaca2 
DNA, 
Control 
DNA 
10X QIAGEN PCR buffer with 
Coral Load PCR Buffer (Qiagen) 
1 
MSP Forward Primer (10μM) 0.4 
MSP Reverse Primer (10μM) 0.4 
dNTP(10mM)  0.2 
0.5 U of Hot Start Taq  
(5U / μl) 
0.1 
Template 
 (5ng / μl) 
0.5 
Nuclease-free water Up to 10 
 
Table 3.9 Program Used for Touchdown MSP 
Step Temperature 
(°C) 
Duration Cycles 
Polymerase 
activation 
95 15min Hold 
Denature 94 30 s  
20 Anneal/Extend 53 30 s 
Elongation 72 15 s 
Denature 94 30 s  
15 Anneal/Extend 43 30 s 
Elongation 72 15 s 
Final Elongation 72 5mins Hold 
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3.7. Methylation-dependent validation 
3.7.1. Demethylation treatment 
Demethylation optimization: In order to establish an unmethylated control, Panc1 and 
Miapaca2 cells were treated with the DNA methyltransferase inhibitor 5-Azacytidine. 
Since the agent has a negative impact on cell survival, the concentration of 5-
Azacytidine was determined by using a resazurin-based cell viability assay. The 
optimization aimed at determining the highest possible concentration of 5-Azacytidine 
that did not reduce cell viability by more than 50 % at the end of 136h treatment. Firstly, 
a standard curve for the viability assay was established. Therefore, 0, 750, 1500, 3000, 
6250, 12500, 25000, 50000 or 100000 cells per well of each cell line were seeded into 
96-well plates, and the cells were cultured in the cell culture incubator for 4h. Afterward, 
resazurin was added to each well with a final concentration of 20μg/ml. The cells were 
incubated for 1 h in the cell culture incubator to allow for the reduction of resazurin to 
resorufin. Finally, the fluorescence was measured in triplicates at an excitation 
wavelength of 544 nm and an emission wavelength of 590 nm using the plate reader 
FLUOstar Galaxy. For the viability assay, 5*103 cells of Panc1 or 6*103 cells of 
MiaPaCa2 were seeded into each well of 96-well plates. 3 biological replicates were 
prepared for each measurement. After 24 h, the culture medium was replaced with 
complete culture medium containing 0μM, 0.5μM, 1μM, 2μM, 4μM, 6μM, 8μM or 10μM 
of 5-Azacytidine. Due to the instability of 5-Azacytidine, the medium was refreshed 
every 24 h. Finally, the cell viability was measured at the start of the treatment, 40 h, 
64 h, 88 h, 112 h and 136 h after the first treatment. The number of viable cells was 
calculated from the relative fluorescent units referring to the standard curve. The 
significance was assessed using a one-sided, unpaired, heteroscedastic Welch's t-
test to compare the 0μM control group with the treated groups. P-values of less than 
0.05 was considered statistically significant. 
 
Demethylation treatment and validation: To obtain DNA and RNA from demethylated 
cells, 2*105 cells of Panc1 or MiaPaCa2 per well were seeded into 6-well plates. 
Complete culture medium containing 0μM, 1μM, or 2μM 5-Azacytidine for Panc1 and 
0μM, 0.5μM, or 1μM 5-Azacytidine for MiaPaCa2 were refreshed every 24 h 
respectively. 72 h after the treatment, the DNA and RNA were isolated using the 
AllPrep DNA/RNA Mini Kit according to manufacturer’s recommendations. For each 
Methods 
 63 
 
sample, 1μg of isolated DNA was used for bisulfite conversion with the EpiTect 
Bisulfite Kit. To verify the demethylation, MSP targeting ALDH1A3 region was 
performed as written in 3.6.2. 
 
RNA isolation and q-PCR: 1ug RNA isolated from last step was used for the cDNA 
synthesis as written in 3.3.4. Quantitative real-time PCR reaction was performed as 
written in 3.3.4. HPRT1 was used as a housekeeping gene for all the samples. Primer 
ALDH1A3 was used to detect mRNA regulation upon the 5-Azacytidine treatment. The 
q-PCR result was analyzed via DDCt method. 
 
3.7.2. Luciferase assay 
Vector cloning: To obtain the identified promoter region of ALDH1A3, a PCR using the 
NFATc1_promoter primer pair was performed. The PCR product was purified by using 
the PureLink Quick PCR Purification Kit. Afterward, 1 µg of the vector pCpGL-basic as 
well as the PCR product were digested by BglII and NcoI enzymes. Next, the digested 
products were extracted by using the QIAquick Gel Extraction Kit following the kit’s 
instructions. After the purification, the PCR product was ligated with the pCpGL-basic 
plasmid using a vector to insert ratio of 1:3. In the end, 1 µL of the ligation mix were 
used to transform 20 µL of PIR1 chemically competent E.colis. 100 µL of the cells 
were plated on pre-warmed LB agar plates containing 0.1 % of zeocin. Subsequently, 
colony PCR was used to confirm the positive clones by using pCpGL_For and 
pCpGL_Rev primers. In the end, the correct insertion was confirmed by sanger 
sequencing.  
 
In vitro methylation: The plasmid containing the ALDH1A3 identified promoter region 
was methylated by incubating 2 µg plasmid DNA with 4 units of M.SssI, 1X NE Buffer 
2 and 320 µM S-Adenosylmethionin at 37 °C for 3 hours. Subsequently, a 5 µL 
reaction mix containing 2 Units of M.SssI, 1X NE Buffer 2 and 12.8 mM of SAM were 
added. The reaction system was incubated at 37 °C for 3 hours followed by 65 °C for 
20 minutes. The methylated DNA was purified using the PureLink Quick PCR 
Purification Kit.  
 
To verify the methylation the plasmid was digested using the methylation-sensitive 
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enzyme BstUI which only cuts unmethylated DNA. Due to the lack of a restriction site 
of this enzyme in the pCpGL-basic plasmid, therefore a plasmid containing the BstUI 
restriction site was used as a positive control. For the digestion 200 ng of plasmid DNA, 
1X Cut Smart Buffer and 5 units of BstUI were filled up with nuclease-free water to a 
20 µL reaction mix which was incubated at 60 °C for one hour.  
 
Cell experiments: In terms of the knockdown cells, cells were grown to a confluency 
of 30-50% before NFATc1 knockdown was performed. In terms of the normal cells, 
cells were grown to a confluency of 80-90% before the luciferase constructs 
transfection. Next, the cells were allowed to grow further for 24 h and then transfected 
with the luciferase constructs. After incubation for 24 h, the cells were harvested and 
the luciferase activity measured, using the Dual-Luciferase Reporter Assay kit 
(Promega). 
 
3.7.3. Chromatin immunoprecipitation (ChIP) 
Panc1 and Miapaca2 cell lines were cultured in 15cm petri dish in their respective 
growth medium to about 80% confluency. Meanwhile, for the demethylation control 
group, Panc1 and Miapaca2 cells were treated with 2μM and 0.5 μM 5-Azacytidine 
respectively for 10 days, and the medium was refreshed every 24hours. When cells 
were demethylated, the cells were fixed with 37% paraformaldehyde at a final 
concentration of 1% for 10 minutes. Glycine solution was incubated with fixed cells for 
5 minutes to quench the fixative at a final concentration of 125mM. The cells were then 
washed twice with 10ml ice-cold PBS. The cells were scraped into 2ml ice-cold PBS 
containing 1x protease and phosphatase inhibitors. The cell pellets were collected by 
centrifuging at 2000g in a benchtop centrifuge at 4°C for 5 min. The ChIP was 
performed using the SimpleChIP Enzymatic Chromatin IP Kit (Magnetic Beads) 
according to manufacturer’s recommendation. Briefly, approximately 4*106 Panc1 
cells and 8*106 Miapaca2 cells were used as one ChIP reaction. After the cell nuclei 
was isolated, the chromatin for each reaction was digested with 0.25 µl micrococcal 
nuclease at 37°C for 20 min. The sonication was then carried to lyse the nuclei on the 
lowest power setting of the Sonoplus-sonicator with 3-6 rounds of 20s pulses and 30s 
breaks. The water bath was cooled with ice. After the lysate clearance by 
centrifugation at 9400 x g for 10 min at 4°C, 10 micrograms chromatin was diluted in 
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400µl of 1x ChIP buffer. Afterward, 5 micrograms of ChIP-grade anti-NFATc1 antibody 
was added and incubated with chromatin at 4°C overnight; as a control for unspecific 
binding, a complex mixture of mouse IgGs was applied. Protein-DNA complexes were 
captured with ChIP-grade protein-G magnetic beads for 4h; unbound protein was 
washed away. Immunoprecipitants were eluted from the beads in 150 µl ChIP elution 
buffer for 30 min at 65°C. The crosslinking was reversed with 200 mM NaCl at 65°C 
for 2 hours, the DNA purified with spin columns and stored at -20°C. Enrichment at 
the ALDH1A3 promoter was determined by qPCR. The ALDH1A3_ChIP primer pair 
was used. PCR was carried out on a LightCycler 480. Three technical PCR replicates 
were carried out for each sample. The percent input method was used for 
normalization. 
 
3.7.4. Statistical analysis  
All experiments were done three or more times. If no extra information was indicated, 
data were shown as mean ± standard error mean. Two-tailed Student’s t test was used 
to make comparisons between 2 different groups. Significant difference was defined 
differently based on different experiments. Statistical analysis was done using 
GraphPad Prism.  
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4 Results 
4.1 The identification of hypermethylated-overexpressed 
genes 
4.1.1 The integration analysis of tissue data 
The methylation profiling and the expression profiling of tissue were integrated to 
identify the hypermethylated and upregulated genes. For this purpose, the mRNA 
profiles of 195 PDAC patients and 41 healthy donors were analyzed, and 6068 
significantly regulated transcripts were chosen. The methylation profiling of 26 PDAC 
patients and 24 healthy donors were analyzed, and 2917 significantly differentially 
methylated promoters were chosen. To calculate the methylation value of promoter 
regions, the methylation value of probes in the defined regions was averaged. After 
integration, 421 transcripts showed the results. 132 transcripts showed 
hypermethylation and downregulation in the expression level; 119 transcripts showed 
upregulation in the expression level and hypermethylation. To select the candidates 
for the next step, genes which showed upregulation in expression and had most 
probes indicating hypermethylation in the defined promoter region were chosen. 
Each dot represents one transcript with the expression and methylation value. X-axis: The log fold 
change of PDAC-patients group relative to healthy-donors group. Y-axis: The mean delta beta value in 
the defined promoter region (-1500/+500bp) when comparing PDAC group with healthy group. The 
shades of color indicate the number of probes.  
Figure 4.1 Integration of expression and methylation profiling 
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4.1.2 The GO enrichment analysis of hypermethylated and 
upregulated genes 
In order to understand the functional role of genes which showed hypermethylation 
and upregulation in PDAC-patients group compared with healthy-donors group, the 
list of 119 genes were used as input for the gene ontology (GO) term enrichment 
analysis. Top 10 overrepresented biological process were shown here.  
 
Figure 4.2 Pathway analysis of upregulated and hypermethylated genes   
Gene ontology term enrichment analysis indicated that hypermethylated and upregulated genes were 
significantly enriched in multiple biological process (top 10 overrepresented process were shown here). 
The threshold was set to False discovery rate (FDR) adjusted P value which was equal with 0.05.  
 
4.2 The identification of methylation-dependent TFs 
4.2.1 Protein microarray 
TF protein microarrays were generated, which covered 4 full-length TFs and 667 DNA 
binding domains from over 12 different TF families (Fig.4.3A). In the end, the full 
expression of proteins was assessed by the immunostaining which used fluorescent 
antibodies against 6xHis-tag of N-terminus and V5-tag of C-terminus. If the fluorescent 
signal intensity of C-terminus was above the threshold, the proteins were considered 
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as successfully expressed proteins. As such, more than 97% TFs were successfully 
expressed (Fig.4.3B, C).  
 
(A) The expressed DBDs were listed according to the family they represent. (B) Proteins were 
immunoassayed with fluorescently labelled antibodies that targeted terminus tags. Green: Anti-V5 Ab, 
C-terminus. Red: Anti-His Ab, N-Terminus, Yellow: Both (anti-His and anti-V5) Abs. Spots in the blue 
rectangle: PCR negative control, Spots in the purple rectangle: blank control. (C) Read out: Median 
Fluorescence Intensities (MFI). C/N-Threashold: mean MFI (negative controls) + 4 SD (negative 
controls). 
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Figure 4.3 Determination of on-chip protein expression 
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4.2.2 Protein-DNA interaction on microarray 
To identify the methylation-specific transcription factors, the generated protein 
microarray was applied for the protein-DNA interaction. Methylated and unmethylated 
DNA-fragments of 55bp were synthesized and labelled fluorescently with Cy5 and Cy3 
respectively. The methylated and unmethylated fragments were mixed in a ration of 
1:1, and the competition binding screening was performed on the protein microarray. 
It’s revealed that TFs showed different binding ability to DNA with different methylation 
state (Fig.4.4A). As such, TFs which bind preferentially to methylated DNA are called 
methyl-plus TFs, and TFs which bind preferentially to unmethylated DNA are called 
methyl-minus TFs. Next, candidates including top 15 methyl-plus TFs and top 3 
methyl-minus TFs were identified based on the signal ratio which was calculated by 
dividing the methylated (Cy5) and unmethylated (Cy3) signal intensity (Fig.4.4B). As 
for the list of methyl-minus TFs, ELK3, FLI1 and EPAS1 were the top candidates with 
highest signal ratio of the unmethylated signal divided by the methylated signal. 
EPAS1 was excluded since the expression was not successful (Fig.4.4C). Afterward, 
the binding of each candidates was checked individually (Fig.4.4E). As for the top 15 
methyl-plus TFs with highest signal ratio of the methylated signal divided by the 
unmethylated signal, NFATc1, NFATc2 and NFATc3 were the binders which showed 
the highest Cy5 signal intensity (Fig.4.4D). Furthermore, all these 3 TFs belong to 
NFAT TF family. Additionally, they were all successfully expressed (Fig.4.4C).  
 
(A) Incubation of a 55bp fragment resembling the methylated (red) and the unmethylated (green) 
promoter identified specific binding; a merger of the images is shown in yellow. (B) The signal ratio was 
produced by dividing the methylated (methyl-Cy5) and unmethylated (unmethyl-Cy3) signal intensity. 
The red dots or green dots showed the binding candidates which preferred binding with methylated 
fragment or unmethylated fragment. (C)The C-terminus and N-terminus expression of all the candidates. 
(D)The methylation and unmethylation signal intensities of top 15 methyl-plus TFs shown in plot B. NC 
refers to negative control. (E)The methylation and unmethylation signal intensities of top 3 methyl-minus 
TFs shown in plot B. 
Figure 4.4 Protein-DNA interaction on microarray 
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4.2.3 In-silico analysis of promoter sequence 
In order to verify the protein-DNA interaction events, the sequence of the tested DNA 
fragments was analyzed by FIMO algorithm. Based on the predicted motif of TFs 
identified by methyl-SELEX from Yin’s study [23] and the sequence of the DNA 
fragments used on the protein microarray (Fig.4.5A), FIMO algorithm has identified 
the matched TFs. Top 50 most matched TFs were shown here according to the P 
value, NATc1/2/3 were in the top candidate list (Fig.4.5B).  
 
(A) Motifs of top 3 methyl-plus transcription factors (identified by methyl-SELEX assay[23]) are shown 
in comparison with the sequence of screening DNA fragments. (B)Top matched TFs identified by FIMO 
using all the motifs of TFs identified by methyl-SELEX. Red line indicates the P value which is 0.01. 
NFATc1/2/3 are shown in the figure. Little/MethylMinus/MethylPlus/inconclusive refers to the 
little/blocking/promoting/inconclusive effect of methylated cytosine on the binding of TFs according to 
the data from methyl-SELEX. 
 
 
 
 
Figure 4.5 In-silico analysis verified the binding of NFATc1/2/3 to the promoter 
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4.3 The expression pattern of NFATc1 in PDAC and pancreatic 
cancer cell lines 
As known from the 4.2 section, NFATc1, NFATc2, NFATc3 were identified as methyl-
plus TFs. Consequentially, the expression pattern of 3 TFs was explored in pancreatic 
cancer tissues and relevant cell lines. 
4.3.1 Tissue data analysis 
In order to determine the expression pattern of NFATc1, NFATc2 and NFATc3 which 
are the methyl-plus TFs, the mRNA profiling of pancreatic tissues was firstly explored. 
On the Sentrix Human WG-6 array, there are 4 probes representing NFATc1, 2 probes 
representing NFATc2 and 5 probes representing NFATc3. However, NFATc1 was the 
only one to show the significant dysregulation (FDR P value < 0.01, log2FC>0.5). 
NFATc1 was upregulated in PDAC-patients and CP-patients groups relative to 
healthy-donors group (Fig.4.6A). When analyzing the TCGA data and GTEx data, 
NFATc1 was upregulated in PDAC-patients group (red bar) compared with healthy 
control group (grey bar) (Fig.4.6B). Furthermore, in-house data (Fig.4.6C) and online 
TCGA data (Fig.4.6D) both showed that NFATc1 was insignificant differentially 
expressed in different tumor stages.  
 
(A) The in-house mRNA profiling data showed that the mRNA expression level of NFATc1 was 
significantly upregulated in groups of CP and PDAC compared with N group. N refers to control, CP 
refers to chronic pancreatitis, PDAC refers to pancreatic adenocarcinoma; Y axis shows the normalized 
NFATc1 gene expression value originated from the analysis of 195 PDAC, 58 CP and 41 normal tissue 
samples. **** P ≤ 0.0001. (B) The online TCGA data showed the consistent result when comparing the 
PDAC group with N group containing the GTEX data and the control data from TCGA. The red column 
indicates the PDAC group containing 179 tumor samples, the grey column indicates N group containing 
171 healthy samples from TCGA and GTEx. * P ≤ 0.05 (C) Expression dynamics of NFATc1 in different 
PDAC stages. According to the in-house mRNA microarray data, the mRNA expression level of NFATc1 
didn’t show difference in 5 different stages of PDAC. The online TCGA data (D) showed the same result.  
 
Figure 4.6 NFATc1 is upregulated in PDAC 
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4.3.2 The expression of NFATc1 in pancreatic cancer cell lines 
The mRNA and protein expression of NFATc1 were explored in 6 pancreatic cancer 
cell lines including Panc1, BxPC3, Miapaca2, AsPC1, Capan1, and Suit2, as well as 
one control healthy cell line HPDE. The q-PCR result indicated that the expression of 
NFATc1 was significantly higher in Panc1 when comparing to HPDE (P< 0.0001, 
Fig.4.7A). RNA was isolated from two batches of cells, and the experiments were 
repeated twice independently. The western blot result indicated that the expression in 
protein level was consistent with the RNA level (Fig.4.7B). 
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Figure 4.7 NFATc1 expression analysis in PDAC cancer cell lines 
(A) Quantification of NFATc1 in mRNA level. The mRNA expression of NFATc1 in 6 pancreatic cancer 
cell lines and the healthy control cell line HPDE. The q-PCR result showed the expression of NFATc1 
in Panc1, Miapca2, Aspc1, Capan1, and suit2, when compared with HPDE, ****P < 0.0001. (B) 
Quantification of NFATc1 in protein level. The protein expression of NFATc1 was analyzed in 6 
pancreatic cancer cell lines and HPDE. The western blot result showed the consistent result as the q-
PCR result.  
 
4.4 The Functional study of NFATc1 ex vivo 
As known from result 4.3, NFATc1 was significantly upregulated in PDAC and CP 
groups relative to the control group. Moreover, NFATc1 was significantly upregulated 
in Panc1 cell line compared with HPDE cell line and it was also expressed in Miapaca2 
cell line. As such, viability assay, migration assay, colony assay, and apoptosis assay 
were performed in Panc1 and Miapaca2 in order to understand the functional role of 
NFATc1 in pancreatic cancer development. 
 
4.4.1 NFATc1 downregulation inhibited the cell viability  
The siRNA-mediated knockdown (KD) cell model was applied for the viability assay. 
The result of western blot confirmed the knockdown of NFATc1 in Panc1 and 
Miapaca2 (Fig.4.8A). The cell viability was studied using resazurin assay. Via 
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determining relative fluorescence units (RFUs) between control and KD treatment 
groups, the results showed that the downregulation of NFATc1 inhibited the cell 
viability significantly and this inhibition effect was increasing in the process of culturing 
time (Fig.4.8B).  
 
Figure 4.8 NFATc1 downregulation decreased the cell viability 
(A)The knockdown of NFATc1 in Panc1 and Miapaca2 cell lines. The western blot result showed that 
the expression of NFATc1 was reduced upon the siRNA-mediated KD of NFATc1. (B) The viability 
assay result in NFATc1-KD Panc1 and Miapaca2 cell lines. The data was collected in a range of 4 days. 
The result showed that the viability was inhibited upon the knockdown of NFATc1. *P ≤ 0.05, **P ≤ 0.01, 
and scr indicates the scrambled siRNA.  
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4.4.2 NFATc1 downregulation decreased the cell migration 
To investigate the effects of siRNA-mediated knockout of NFATc1 in Panc1 and 
Miapaca2 cell lines on the migration ability of cells, trans-well plates were used in the 
study. After the crystal violet staining, it was obviously shown that the NFATc1 
downregulation decreased the cell migration (Fig.4.9A). All the images were analyzed 
by image J and the result indicated that NFATc1 significantly promoted the cell 
migration in Panc1 and Miapaca2 cell lines (Fig.4.9B).  
(A)The crystal violet staining of transwell with siRNA-mediated cells. siRNA refers to siRNA-mediated 
knockdown against NFATc1 in Panc1/Miapaca2 cells, and scr refers to the negative control which are 
the cells transfected by scrambled siRNA. Scale bar=50μm. (B) The migration ability was decreased 
significantly upon the KD of NFATc1. The staining area was analyzed and each dot in the bar 
represented the staining (quantified by raw integrated intensity indicated in image J). The result of image 
analysis showed that ***P≤0.0001.  
 
4.4.3 Apoptosis assay 
The siRNA-mediated knockdown of NFATc1 in Panc1 and Miapaca2 was examined, 
and the effect of NFATc1 on the apoptosis was studied by AnnexinV-PI assay. Cells 
which showed the signals of AnnexinV-positive and PI-negative were in the stage of 
the early apoptosis, while cells which showed AnnexinV-positive and PI-positive 
Figure 4.9 NFATc1 downregulation decreased the migration assay 
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signals were in the stage of the late apoptosis. The cell events in different stages were 
counted respectively (Fig.4.10A). The results showed that in Panc1, the knockdown 
of NFATc1 significantly increased the percentage of cells in both early and late 
apoptosis stage. While in Miapaca2, the knockdown of NFATc1 only increased the    
percentage of cells in late apoptosis stage significantly (Fig.4.10B).  
 
(A) FACS analysis of apoptosis assay. Representative flow cytometry scatter plots of propidium iodide 
(PI) (Y axis) vs Annexin-FITC (X axis). Cells shown in Q1/Q2/Q3/Q4 were in the dead /late apoptosis 
/early apoptosis /live stage. (B) The apoptosis assay was performed on Panc1 and Miapaca2 cell lines 
with siRNA-mediated knockdown of NFATc1. The percentage of cells in late or early apoptosis stage 
was calculated respectively and siRNA group was compared with the control group. *P ≤ 0.05, **P ≤ 
0.01. 
Figure 4.10 Apoptosis assay 
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4.4.4 Colony assay 
The stable overexpression (OE) and knockout (KO) of NFATc1 in Panc1 and 
Miapaca2 were studied in colony assay. Western blot confirmed the reliability of both 
KO and OE (Fig.4.11A, B). The colonies were stained by crystal violet and counted 
well by well. The results showed that the colony formation ability was decreased upon 
the knockout of NFATc1 in Panc1 and Miapaca2 when compared with the control 
group (Fig.4.11C). In terms of compensation experiments, the number of colonies was 
increased upon the OE of NFATc1 when compared with the control group (Fig.4.11D).  
 
(A) CRISPR-Cas9 mediated KO of NFATc1 was confirmed by western blotting. (B) The NFATc1-OE 
cell lines were established by using the lentivirus tool and the stable OE cell lines were confirmed by 
western blotting. The colony assay was performed using (C) the stable KO cell lines and (D) stable OE 
cell lines. The crystal violet staining was performed 3 weeks after the seeding. The colonies were 
counted and shown in the bar blot, *P ≤ 0.05, **P ≤ 0.01.  
 
 
 
Figure 4.11 Colony assay 
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4.5 The pathway and candidate analysis of NFATc1  
As indicated in the 4.4 section, the downregulation of NFATc1 inhibited the cell viability, 
decreased the cell migration, blocked the ability of colony formation, and increased 
the percentage of apoptotic cells in Panc1 and Miapaca2 cell lines. It’s concluded that 
NFATc1 exerted an oncogenic function and showed the importance in the process of 
carcinogenesis. Subsequently, in order to investigate the involved pathway of NFATc1 
and identify the targets of NFATc1, a genome-wide microarray-based transcriptomic 
profiling was conducted in three PDAC cell lines (Panc1, Miapaca2 and AsPC1) that 
were pre-transfected with siRNA against NFATc1 and scramble RNA.  
 
4.5.1 Pathway analysis 
A gene set enrichment analysis was performed on the basis of the Illumina HT12 
transcriptomic profiling collected from control cells and NFATc1-knockdown cells. 
When the analysis was referred to the 50 hallmark gene sets (Fig. 4.12A), multiple 
gene sets which are associated with Myc targets, P53 pathway, E2F targets, G2M 
checkpoint, and DNA repair were significantly enriched in the control cells compared 
with NFATc1-knockdown cells. When the analysis was referred to the KEGG pathway 
(Fig. 4.12B), various metabolism related pathways, including drug metabolism 
(cytochrome P450 and other enzymes), purine metabolism and pyrimidine metabolism 
were highly enriched in control cells compared with NFATc1-KD cells. Besides, 
pathways associated with transcription, DNA replication, spliceosome, mismatch 
repair, none small cell lung cancer, cell cycle, ribosome, acute myeloid leukemia, 
ERBB signaling pathway and proteasome were also detected with higher enrichment 
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in control cells. The result of pathway analysis confirmed the oncogenic role of 
NFATc1 in pancreatic cancer cell lines.  
(A) Hallmark gene set enrichment analysis and (B) KEGG gene set enrichment analysis based on the 
transcriptomic profiling. Both analysis approaches predicted pathways and activities that were 
significantly enriched in control cells compared with NFATc1 knockdown cells. The normalized 
enrichment score (NES) was used to compare analysis results across gene sets.  
 
4.5.2 Identification of target genes  
To further investigate the targets of NFATc1 and methylation-dependent 
transcriptional regulation of NFATc1, differential expression analysis was primarily 
performed between control cells and NFATc1-knockdown cells. Top 30 candidates 
that showed consistently downregulated expression upon the KD of NFATc1 in Panc1, 
Miapaca2 and AsPC1 cell lines were listed in the heatmap (Fig.4.13A). Afterward, it’s 
identified that 3 genes (ALDH1A3, ALDH3A1, AGR2) out of 30 downregulated genes 
were upregulated with hypermethylated probes in promoter regions in PDAC tissues 
compared with healthy tissues. (Fig.4.13B). Subsequently, methylated/unmethylated 
motif of NFATc1 and sequence of promoter(-2000bp/500bp) of 3 candidate genes 
were matched based on FIMO algorithm to identify potential binding sites. In the 
promoter region of ALDH1A3 (-1035bp/893bp), multiple methylated and unmethylated 
binding sites of NFATc1 were identified (Fig.4.13C). Moreover, the methylation data 
of PDAC tissues was also taken into consideration. Ultimately, ALDH1A3 was 
identified as a potential methylation-dependent target of NFATc1. 
Figure 4.12 Pathway analysis 
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(A) Heatmap showing the genes that were consistently down-regulated upon the knockdown of NFATc1 
in 3 pancreatic cancer cell lines. Each column represents the results obtained in Panc1, Miapaca2 and 
AsPC1 (left to right). In addition, transfection with an siRNA of scrambled sequence are shown here as 
control (Ctrl). (B) The overlap between the top upregulated genes upon the knockdown of NFATc1 in 3 
pancreatic cancer cell lines and upregulated transcripts with hypermethylated probes in promoter region 
from PDAC tissues. (C) FIMO identified significantly matched methylated/unmethylated NFATc1 
binding sites in the promoter region of ALDH1A3. The CpG sites were colored in red.  
 
4.6 Validation of ALDH1A3 
It is shown in the 4.5 section, multiple cancer associated pathways were enriched and 
ALDH1A3 was selected as a candidate which was downregulated upon the 
knockdown of NFATc1. In addition, the potential methylated binding sites of NFATc1 
were identified in the promoter region of ALDH1A3. It’s hypothesized that ALDH1A3 
was upregulated by NFATc1 in pancreatic cancer tissue cell lines due to the binding 
of NFATc1 in the promoter region of ALDH1A3 though the binding sites were 
methylated. To follow-up this hypothesis, the mRNA expression and methylation level 
of ALDH1A3 in tissue and cell lines (Panc1 and Miapaca2) was analyzed. Moreover, 
the expression of ALDH1A3 was assessed upon the regulation of NFATc1. 
Figure 4.13 ALDH1A3 was identified as a target of NFATc1 
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Furthermore, the cells were treated with 5-Azacytidine and the expression of 
ALDH1A3 was checked. Next, the promoter activity of the predicted region was 
analyzed by luciferase assay with the methylated or unmethylated construct. 
Subsequently, chromatin immunoprecipitation was applied to check if NFATc1 could 
bind in the promoter region of ALDH1A3 ex vivo.  
 
4.6.1 Validation of ALDH1A3 in mRNA level 
In order to validate ALDH1A3 as a target of NFATc1 in Miapaca2 and Panc1 cell lines, 
NFATc1 knockout (KO), knockdown (KD), overexpression (OE) cell models were 
applied to study the expression of ALDH1A3 in mRNA level. As shown in Fig.4.14 A, 
ALDH1A3 was downregulated when NFATc1 was suppressed in Panc1 and Miapaca2. 
While only in Panc1, ALDH1A3 was upregulated when NFATc1 was overexpressed. 
That means that NFATc1 positively regulated ALDH1A3. Additionally, in tissue 
samples, ALDH1A3 was upregulated in PDAC group (Fig.4.14B). While in cell line 
samples, ALDH1A3 was upregulated in HPDE cell line comparing with Miapaca2 and 
Panc1 (Fig.4.14C).  
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Figure 4.14 The expression of ALDH1A3 was regulated by NFATc1 in Panc1 and Miapaca2 
(A) NFATc1 positively regulated the expression of ALDH1A3. q-PCR results showed the expression of 
NFATc1 and ALDH1A3 in knockout (blue bar), knockdown (purple bar) and overexpression (green bar) 
cell models. Sg2 refers to the sgRNA against NFATc1, scr-sg refers to the scramble sgRNA; OE refers 
to the overexpression of NFATc1, ctrl refers to the empty construct; siRNA refers to the siRNA against 
NFATc1, scr-si refers to the scramble siRNA. (B) The mRNA expression of ALDH1A3 in PDAC and N 
group, ****P ≤ 0.0001. (C) Q-PCR results presented the mRNA expression of ALDH1A3 in HPDE, 
Miapaca2 and Panc1 cell lines. 
 
4.6.2 Validation of methylation level 
In order to validate the methylation level of NFATc1 binding sites in the promoter 
region of ALDH1A3, 450k microarray data of tissues and cell lines was analyzed. The 
promoter of ALDH1A3 was deciphered in Fig.4.15A. For the two CpG sites in the 
promoter region of ALDH1A3, the results showed that beta value was significantly 
higher in PDAC group and it’s also significantly higher in Panc1 cell line (Fig.4.15 B, 
C).  
Results 
 84 
 
 
(A) The promoter illustration of ALDH1A3. BS refers to the predicted methylated binding sites of 
NFATc1. cg19224278 and cg23191959 are the CpG probes covered by 450 microarrays and the 
predicted binding sites were located in the position of these 2 CpG sites. TSS refers to the transcription 
starting site, and Primer indicated the site of ChIP-PCR primer. (B) cg19224278 and cg23191959 was 
hypermethylated in PDAC group. ****P ≤ 0.0001, **P ≤ 0.01. (C) The beta value of cg19224278 and 
cg23191959 was almost 4 folds in Panc1 cell line. 
 
4.6.3 Analysis of demethylated cell samples 
To investigate the methylation effect on the expression of ALDH1A3 and the binding 
of NFATc1, the demethylation in pancreatic cancer cell lines was performed by treating 
the cells with 5-Azacytidine drug. For the 5-Azacytidine treatment, the concentration 
was optimized. The growth curve of Panc1 treated by different concentration of 5-
Azacytidine indicated that the optimal dose for the Panc1 was 2µM (Fig.4.16A), and 
the optimal dose for Miapaca2 was 0.5 µM(Fig.4.16B). After 3-day treatment of 5-
Azacytidine drug, the demethylation effect in Panc1 treated with 2µM 5-Azacytidine 
Figure 4.15 The promoter of ALDH1A3 was hypermethylated in tissue and cell lines 
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and Miapaca2 treated with 0.5µM 5-Azacytidine was confirmed by methylation specific 
PCR (Fig.4.16C).  Moreover, for Miapaca2, the expression of ALDH1A3 was 
upregulated in drug treatment group compared with control group, while in Panc1, 
ALDH1A3 was downregulated upon demethylation in Panc1(Fig.4.16D).  
(A-B) The number of viable cells was determined by means of a resazurin assay. The Panc1 cells (A) 
and Miapaca2 cells (B) were either treated with 0 μM, 0.5 μM, 1 μM, 2 μM, 4 μM, 6 μM, 8 μM or 10 μM 
of the demethylating agent 5-Azacytidine. The cell viability was assessed 0 h, 40 h, 64 h, 88 h, 112 h 
and 136 h after the treatment. (C) Methylation specific PCR. 1: Untreated Panc1, 2: Panc1 treated with 
2 μM 5-Azacytidine for 3 days, 3: Panc1 treated with 4 μM 5-Azacytidine for 3 days; 4: untreated 
Miapaca2, 5: Miapaca2 treated with 0.5 μM 5-Azacytidine for 3 days, 6: Miapaca2 treated with 1 μM 5-
Azacytidine for 3 days; PC: positive methylated converted sample; NC: negative control.  (D) The mRNA 
expression of ALDH1A3 was measured in cells treated with and without 5-Azacytidine by q-PCR 
method. **P ≤ 0.01, *P ≤ 0.05. 
 
4.6.4 Luciferase assay 
To investigate the promoter activity of the predicted promoter region of ALDH1A3 (-
1035bp/893bp), luciferase assay was performed accordingly. The predicted promoter 
region was cloned into the luciferase construct followed by the in-vitro methylation. 
Figure 4.16 Analysis of demethylated cell samples 
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Firstly, the assay was studied in NFATc1-high expression cell line-Panc1 and low 
expression cell line-Miapaca2. Comparing with Miapaca2, Panc1 showed significantly 
higher promoter activity. Additionally, the methylated promoter construct still showed 
significantly higher promoter activity compared with the empty promoter construct, 
while the methylation of the promoter decreased the promoter activity (Fig.4.17A). 
Next, the assay was investigated in NFATc1-knockdown Panc1 and Miapaca2 cell 
lines. The activity of unmethylated promoter was decreased upon the knockdown of 
NFATc1 in Panc1 and Miapaca2 cell lines. In terms of the methylated promoter, the 
activity was decreased upon the knockdown of NFATc1 in Panc1, but not in Miapaca2 
(Fig.4.17B). 
Figure 4.17 Luciferase assay 
(A) The relative luciferase activity in Panc1 and Miapaca2 cell lines. After cloning ALDH1A3 promoter 
sequence (from -1035bp to -893bp) into a construct encoding for the luciferase gene. The luminescence 
was measured as an indicator of promoter activity (black and grey bars). Compared with the empty 
construct (NC), both in-vitro methylated (Methyl) and unmethylated (Unmethyl) promoter constructs 
showed high promoter activity in Panc1 and Miapaca2 cell lines. Moreover, there was a clear increase 
of activity in Panc1 in which NFATc1 expression was higher compared with Miapaca2 cell line. (A) The 
relative luciferase activity in Panc1 and Miapaca2 cell lines upon the knockdown of NFATc1. The activity 
of unmethylated promoter (Unmethyl) was decreased upon the knockdown of NFATc1 in both cell lines. 
KD refers to knockdown of NFATc1, and scr refers to the scramble siRNA control. As for the in-vitro 
methylated promoter (Methyl), there was a clear decrease of promoter activity in Panc1 upon the 
knockdown of NFATc1, while not in Miapaca2 cell line.  
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4.6.5 Chromatin immunoprecipitation 
The direct interaction between NFATc1 and ALDH1A3 was confirmed by chromatin 
immunoprecipitation (ChIP). Additionally, ChIP of 5-Azacytidine treated cell samples 
were used to validate the methylation-dependency of NFATc1. Two primer sets were 
used for the ChIP-PCR. Promoter primer set was used to detect the binding of NFATc1 
in the target region, and -5kb primer set located 5kb upstream of the transcription 
starting site was used as a negative control for ChIP PCR. The ChIP-PCR result 
indicated that NFATc1 showed the binding signal in the target region of ALDH1A3 in 
Panc1 samples, and demethylation inhibited this binding event. While in Miapaca2, no 
binding signal was shown (Fig.4.17).  
The binding of NFATc1 with the methylation binding sites in the promoter region of ALDH1A3 was 
determined by ChIP-PCR. The cells with and without 5-Azacytidine treatment were used for the ChIP. 
The result was indicated by percentage input. IgG was the negative control of ChIP. Promoter primer 
set (Blue bar) was used for ChIP-PCR, -5kb primer set (red bar)  was the negative control of ChIP-PCR.  
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Figure 4.18 Chromatin immunoprecipitation 
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5 Discussion 
5.1. Integrative analysis of methylation and expression 
profiling    
DNA methylation is one of the key epigenetic modifications. It plays an important 
developmental role in multiple cancers, including pancreatic adenocarcinoma [126], 
colorectal cancer [127] and breast cancer [128]. The aberrant 5-methylcytosine in 
cancer could introduce the mutation in tumor suppressor gene, and it also induces 
chromosomal instability [129]. Moreover, it is widely known that methylation of 
cytosines is associated with a repressed chromatin state and gene repression [22]. 
However, more evidences suggest another scenario that the hypermethylation in the 
promoter region is not always associated with gene repression [130]. In order to better 
understand the role of DNA methylation as an epigenetic modification in regulating 
gene expression during the development of pancreatic adenocarcinoma, an 
integrative study combining global gene expression and methylation profiles is 
essential. The log-fold change of expression level and the mean delta beta value in 
the defined promoter region (-1500/+500bp) when compared PDAC group with healthy 
group were integrated.  The integrative analysis indicates that 132 hypermethylated 
genes are down-regulated, while 119 genes with hypermethylation are up-regulated 
conversely.  
 
For the genes which showed hypermethylation-related down-regulation, the 
mechanism of gene transcription regulation can be explained by the classical model, 
that methyl-CpG-binding domain proteins recognize methylated CpGs and recruit 
repressor complexes such as a histone deacetylase complex, resulting in histone 
modification and a more condensed chromatin structure which block the transcription 
[131]. However, as for these hypermethylated genes which were up-regulated, the 
classical model couldn’t explain how this enhanced expression was modulated. Firstly, 
in order to understand the function of these genes, gene ontology term enrichment 
analysis was performed. As a consequence, genes in multiple embryonic development 
related processes, such as anatomical structure morphogenesis, embryonic skeletal 
system morphogenesis, and regulation of developmental process were enriched. 
Previous studies indicate that early embryo development and tumorigenesis share a 
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remarkable similarity [132] [133] [134]. Due to the common requirements of cellular 
proliferation and differentiation in oncogenic and embryonic development, epithelial-
to-mesenchymal transition along with the Wnt, Hedgehog, Notch, PAP and BMP 
pathways are widely involved in controlling these similar processes [134]. 
Epigenetically, although genome-wide demethylation is observed in the development 
process of both embryo and cancer, the activity of DNA methyltransferases is highly 
intensive in embryos and tumors. Additionally, multiple genes which are highly 
expressed in embryonic stem cell and essential for early embryonic development are 
also detected in tumorigenesis, instead of in normal cells. Among 119 
hypermethylated and up-regulated genes, Twist1 genes were chosen for functional 
protein microarray screening since they present the most intensive hypermethylation 
probes in the promoter areas. As for Twist1, it encodes a transcription factor involved 
in the regulation of organogenesis and epithelial–mesenchymal transition (EMT) 
pathway. In addition to embryonic development, Twist1 also plays important roles in 
cancer metastasis [135] and cell plasticity in breast cancer [136]. Moreover, its 
hypermethylation was frequently observed in pancreatic cancer and colorectal tumors 
[137] [138]. Concerning that multiple hypermethylated and upregulated genes exert 
multiple biological functions in various cancers, it’s inspiring to further study whether 
and how their up-regulated expressions are correlated with enhanced 
hypermethylation during oncogenic development. To do so, it’s hypothesized that 
certain transcription factors could recognize the methylated promoter of the 
candidates and thus regulate the transcription. 
 
In terms of the method for integrative analysis, in this study, I utilized the strategy 
simply integrating the expression data of one gene with methylation value of its 
promoter. In this strategy, the methylation value is presented by the mean delta beta 
value in the defined promoter region (-1500/+500bp) between PDAC group and 
healthy group. It’s noteworthy that the methylation level of promoters could vary when 
different strategies are adopted. Instead of calculating the mean methylation level of 
defined promoter region, the number of methylated probes which represent CpG sites 
in the defined promoter region including 1st exon, 5’UTR, TSS200 and TSS1500 could 
represent the methylation level of promoters. In a word, one strategy called probe 
integration is based on the individual probe, the other strategy called region integration 
is based on the mean methylation level in the defined promoter region. The region 
Discussion 
 90 
 
integration method comprises a group of neighboring methylation sites, and thus 
indicate a more persistent methylation-based modulation across a defined region. 
While this method might average the methylation of all the probes in the defined 
promoter region and neglect the important individual probes which was associated to 
crucial phenotype. However, the probe integration might have a less predictive feature. 
In this study, the focus is to study the effect of methylation on transcription regulation, 
while promoter is known to be crucial to the transcription initiation of one particular 
gene. Therefore, the most straightforward approach is to use the predefined promoter 
region.  
 
This integrative analysis has identified multiple genes which are upregulated and 
hypermethylated. Moreover, the functional analysis uncovered the crucial role of these 
genes in embryo development. Although recent studies have revealed that pathways 
involved in cancer progress share the embryological characteristics, the regulation 
mechanisms underlying the causal link between hypermethylation and up-regulated 
transcription remain elusive. 
 
5.2. The identification of methylation-dependent TFs 
To reveal how methylation-dependent transcription activation happens, it’s 
hypothesized that TFs could recognize the methylated binding sites and thus regulate 
the transcription. TFs are widely believed to recognize and bind to specific regulatory 
sites on a genome-wide level. Emerging evidences indicate that DNA methylation has 
an impact on the specificities of TF binding and regulates diverse transcription events 
[130]. Our integrative analysis has revealed a number of genes showing 
hypermethylation and upregulation in PDAC. To identify the impact of DNA 
methylation on the gene transcription, the knowledge of TF-DNA (methylated and 
unmethylated DNA) binding comprising the aspects of biochemical affinity, genomic 
context for TF-DNA binding and protein-protein interaction and synergy is required. As 
the first step, the generation of protein microarray covering over 670 different DBDs 
was followed by the protein-DNA interaction screening. In this study, promoter region 
of Twist 1 was applied in the TF protein microarray assay. 
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Firstly, the quality of protein expression on microarray was examined. More than 97% 
DBDs were successfully expressed. In this study, successful expression event on the 
microarray is based on epitope signals against fusion tags on N- and C-terminus, 
especially V5-tag that is fused in the C-terminus of DBDs to guarantee the complete 
translation. However, in some cases, either only one terminus signal or differential 
signal intensities between C-terminus and N-terminus was observed. As reported 
previously [109], the successful tag epitope-antibody bindings are restricted with 
protein folding on the array and the attachment of tagged DBDs to the solid support. 
Moreover, in most cases, the interaction between the protein and DNA is based on 
the interaction between the epitope of the protein and DNA, while not the complete 
structure of the protein. 
 
Secondly, the result of protein-DNA interaction was analyzed. Top 15 methyl-plus TFs 
and top 3 methyl-minus TFs were selected for detailed check. This result supports the 
hypothesis that DNA methylation has an impact on the specificities of TF binding and 
TFs lacking the methyl-binding domains are also able to bind with methylated motif.  
ELK3, FLI1 and EPAS1 are identified as methyl-minus TFs which preferentially bind 
with un-methylated motif. Interestingly, ELK3 and FLI1 both are in ETS family. Another 
methyl-minus TF EPAS1 contains a basic-helix-loop-helix (bHLH) domain, which is 
also named HIF-1alpha-Like Factor or HIF2a. Additionally, it’s reported to induce 
genes expression by oxygen [139]. Comparing with the DNA sequences loaded on 
the microarray, 5'-TCCGTG-3' is identified with high similarity as the core DNA 
sequence of EPAS1, which was 5'-TACGTG-3' within the hypoxia response element 
(HRE) of promoter. Functionally, HIF1a is reported to increase invasiveness and 
metastasis by directly regulating Twist1 [140], and moreover, HIF1a and EPAS1 are 
structurally similar in binding motifs. A recent study from the methyl-SELEX has 
consistently identified that the binding of ETS-family and bHLH family TFs are 
generally blocked by mCpG [23]. On the contrary to the methyl-minus TFs, methyl-
plus TFs, including NFATc1, NFATc2 and NFATc3 preferentially bind with methylated 
motif. NFATc1,2,3 share homology with each other and all belong to nuclear factor of 
activated T-cells (NFAT) family, which plays a crucial role in inducible gene 
transcription during immune response. In contrast to methyl-minus TFs, the methyl-
SELEX reveals that NFAT family TFs prefers to bind with mCpG-containing 
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sequences [23]. Additionally, FIMO analysis has identified the consensus sequence 
of NFAT family TFs in the promoter region of Twist1.  
 
In recent years, multiple methods have been applied to study the impact of methylation 
on the TF binding. In 2013, it’s revealed that DNA methylation presents distinct binding 
sites for human transcription factors by the means of protein microarray [89]. They 
have identified numerous human TFs across various subfamilies that showed mCpG-
and sequence-dependent binding activity. This is the first sophisticated study after 
prevalent phenomenon was discovered [141]. However, there are some limitations in 
this work. Firstly, only 150 CpG-containing motifs with known sequences are surveyed 
in the study, and none of novel TF motifs are identified. Secondly, the motif used in 
this study are with short length and thus no TF heterodimers are formed properly. 
Thirdly, this protein microarray strategy produces ∼27% of false positives and certain 
false negative. Fourthly, methylated CHG, CHH sequences or hemimethylated DNA 
motifs that are available in vivo are not studied. In 2017, the impact of cytosine 
methylation on DNA binding specificities of human transcription factors has been 
systematically studied by means of methylation sensitive SELEX [23]. This is the most 
systematical study aiming to discover the motif of human TFs with the impact of 
cytosine methylation, and the coverage of individual TFs is considerably higher than 
previous systematic studies [142] [27]. In their study, methylation-sensitive SELEX is 
used to explore the binding affinity of 542 human TFs. Compared to the other methods, 
SELEX is able to detect longer binding motif and identify the novel motifs based on 
the high complexity of the input library. However, some limitations should be 
considered. Firstly, the method mainly measures enrichment of sequences but not the 
affinity of binding. Additionally, there might be bias introduced by PCR in each round 
of enrichment because of different DNA context.  
   
Briefly, in this study, I utilized the strategy of combining the cell-free based protein 
expression with the functional screening on the protein microarray. In previous protein 
microarray-based study, it is a tedious work to express, purify and spot multiple 
proteins separately. In this study, more than a thousand protein could be expressed 
on the microarray simultaneously by means of cell-free expression system. This high-
throughput expression platform highly boosts the screening efficiency of functional 
protein microarray. Novel DNA-binding activities could be discovered by this method. 
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Furthermore, unlike DNA microarray-based protein-DNA interaction assay and SELEX 
assay, the DNA fragments used in our study have the same sequence as one piece 
of genome. In this way, the protein-DNA interaction could partly mimic the in vivo DNA 
binding activities. However, this method also has some limirations: Firstly, the 
functional protein microarray couldn’t quantify the affinity of a protein to double-
stranded DNA (dsDNA), and the screening results only indicate whether the proteins 
could bind with DNAs. In this study, MeCP2 and MBD1 are used as positive controls 
on the microarray for the methylation-dependent TF bindings. As a consequence, the 
very week binding signals in the competition screening are probably due to the low 
affinity of these proteins to methylated dsDNA on the microarray. Secondly, this 
method lacks the ability to discover novel TF motifs as that SELEX demonstrates, and 
the genomic DNA fragments used exclusively here were from the integrative analysis 
of methylation and expression profiles. Despite the advantage of supporting long DNA 
fragments on the microarray, this approach fails to localize the binding site in the long 
DNA fragment since DNA of only 8-mer is enough for the TF binding. 
 
My findings demonstrate that methylation has an impact on the binding of TFs. 
Consistent with the results from Yin et al. in 2017[23], It’s discovered that NFATc1, 
NFATc2 and NFATc3 are methyl-plus TFs which preferentially bind with methylated 
motifs, while ELK3, FLI1 and EPAS1 are identified as methyl-minus TFs which 
preferentially bind with unmethylated motifs. This study provides a reliable framework 
to better understand the binding activities of TFs. Furthermore, efforts are put on the 
biological significances of methylation-dependent NFAT family TFs since methyl-
SELEX-based systematic investigations have revealed the binding motif of 542 human 
TFs that are cytosine methylation-dependent, while the mechanisms of DNA 
methylation-dependent regulation are still not clear yet.  
 
5.3. NFATc1 exerts the oncogenic role in pancreatic cancer cell 
lines 
Nuclear Factor of Activated T Cells 1, NFATc1 or NFAT2, was firstly identified in 
activated T cells which acts as an inducible nuclear factor via binding the iterleukin-
2(IL-2) promoter [143]. With more emerging evidences, it’s revealed that genes 
expression in NFAT family are not limited in T cells. Even though NFAT proteins are 
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principally characterized in immune cells, they function in diverse cell types including 
non-T cells of immune system and non-immune cells [144] [145]. In this study, new 
evidences of the functional role of NFATc1 in pancreatic cancer cell lines are provided.  
From the functional protein microarray screening, NFAT family TFs including 
NFATc1,2,3 were identified as methyl-plus TFs. The NFAT family consists of five 
members: NFAT1,2,3,4,5, and NFAT1-4 are regulated by calcium signaling. All NFAT 
proteins have a highly conserved DNA-binding domain, which explains that NFATc1-
3 present binding signals to the same methylated promoter. During T-cell activation, 
most cytokine genes are regulated by NFAT proteins. Moreover, it is clearer now that 
NFAT proteins are also involved in many other signaling pathways and their target 
genes control cell-cycle progression and activation-induced cell death [146]. However, 
more evidences are needed. On the basis of NFAT family characteristic of binding with 
methylated motif, the identification of methylated targets of NFATc1 will lead to a full 
understanding on how NFAT family TFs function in non-immune cells.  
 
Initially, the expression of NFAT family TFs was investigated in pancreatic cancer 
tissues, chronic pancreatic tissues, healthy pancreatic tissues and also pancreatic 
cancer cell lines. The in-house data indicates that the expression of NFATc1 is up-
regulated in PDAC and CP tissues, either than healthy tissues. However, no PDAC 
stages-related expression variations is observed. Concerning pancreatic cancer cell 
lines, NFATc1 is detected in the cell lines originating from primary tumor (Panc1, 
BxPC3 and Miapaca2), ascites (AsPC1) and from liver metastasis (Capan1 and Suit2). 
Interestingly, compared with the healthy cell line HPDE, the expression of NFATc1 is 
significantly upregulated in Panc1. Notably, NFATc1 is comprised of five mRNA 
transcript variants known to encode three different protein isoforms. The mRNA 
encoding isoform C (mRNA variant 3) was the most expressed followed by isoform B 
(mRNA variant 5). While, Isoform A (mRNA variant 1) and mRNA variants 2 and 4 
made up less than 1% of the total NFATc1 expressed [147]. From the results of 
western blot, no single sharp band was observed. Instead, multiple protein isoforms 
were detected. In recent studies, besides inflammatory cell lines, NFATc1 is widely 
expressed in various tumor cells and promotes the invasion of many tumor cells from 
different cancer type. In Tsukasa’s study, NFATc1 is detected in a small proportion of 
tumor cells in human carcinoma specimens, and overexpression of NFATc1 has 
promoted cancer cell invasion and caused associated changes in cell morphology 
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[148]. In colon cancer and pancreatic cancer, NFATc1 induces the expression of c-
Myc and cyclinD, which facilitates TGFβ-promoted cell growth [149] [150]. On the 
contrary, inhibition of NFATc1 in human and mouse colon cancer cells results in 
decreased invasiveness in vitro, and also downregulation of metastasis-related 
network genes. Similar with the conclusion from human carcinoma specimens, 
overexpression of NFATc1 has significantly increased the metastatic potential of colon 
cancer cells [151]. Moreover, loss of NFAT1 expression in breast cancer cell lines 
using small interfering RNA leads to attenuated transcription of COX-2 and reduced 
invasion level as in other cases [152].  
 
In this study, I investigate the function of NFATc1 in the overexpression, sgRNA-
mediated knockout, and siRNA-mediated knockdown cell models. For Panc1 and 
Miapaca2, suppression of NFATc1 inhibits the cell viability, reduces the cell migration, 
and promotes the apoptosis. As for the overexpression, isoform A of NFATc1 was 
overexpressed. Modulations of NFATc1 expression level via knockout, knockdown 
and overexpression suggest that the expression of NFATc1 is positively associated 
with colony formation. Functional assays support oncogenic roles of NFATc1 in Panc1 
and Miapaca2. In pancreatic cancer, it’s reported that oncogenic mutations in KRAS 
contribute to the development of PDAC but are not sufficient to initiate carcinogenesis. 
Additionally, inflammation-induced signaling via the epidermal growth factor receptor 
(EGFR) and expression of SOX9, is essential for the tumor formation. Furthermore, 
exocrine pancreatic cells affect the tumor progression by changing the cellular 
phenotype. Chen et al. reveal that EGFR signaling induces expression of NFATc1 and 
Sox9, and furthermore leads to acinar cell trans-differentiation and initiation of 
pancreatic cancer [153]. Moreover, EZH2 positively regulates the oncogenic activity 
of NFATc1, which is an important mechanism of pancreatic cell plasticity [154].  
 
This and previous studies have revealed the oncogenic function of NFATc1 beyond 
inflammation function. While the targets of NFATc1 is not revealed in pancreatic 
cancer.  In order to further understand the mechanism of oncogenic initiation, the 
NFATc1-associated pathways and the targets of NFATc1 are investigated. The mRNA 
profiling is conducted in siRNA-mediated knockdown cell lines including Panc1, 
Miapaca2 and AsPC1. When the analysis was referred to 50-hallmark gene sets, 
multiple gene sets associated with Myc targets, P53 pathway, E2F targets, G2M 
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checkpoint, and DNA repairment pathways are significantly enriched in the control 
cells compared to NFATc1-knockdown cells. When the analysis was referred to KEGG 
pathways, various metabolism related pathways, including drug metabolism 
(cytochrome P450 and other enzymes), purine metabolism and pyrimidine metabolism 
are highly enriched in control cells compared with NFATc1-KD cells. These results 
suggest the oncogenic role of NFATc1.  
 
Next, the targets of methylation-dependent transcription factor NFATc1 are identified 
by integrating data of the knock-down profiling, and methylation profiling of PDAC 
tissues, Panc1 and HPDE cell line. Although functional protein microarray data 
indicates that NFATc1 is a reader of methylation promoter of Twist1, Twist1 is not 
regulated by NFATc1. Interestingly, the expression of Twist1 is not further detected in 
Panc1 and Miapaca2 cell lines, even though the expression of Twist1 is upregulated 
in PDAC and the microarray screening demonstrates the potential causal link between 
its hypermethylation and upregulation in PDAC tissues. The heterogeneity in tissues 
might explain this phenomenon. Ultimately, ALDH1A3 is identified as a potential target 
of NFATc1 since the transcription of ALDH1A3 is regulated positively by NFATc1, and 
multiple methylated NFATc1 binding sites at ALDH1A3 promoter region are 
speculated. Additionally, MKNK2 is also a potential target of NFATc1 since multiple 
unmethylated NFATc1 binding sites at ALDH1A3 promoter region are identified. 
Subsequently, further functional evidences validate ALDH1A3 and MKNK2 as the 
targets of NFATc1. 
 
5.4. Revealed model of transcription regulation by NFATc1 
Notably, the expression of ALDH1A3 is positively regulated upon knockdown, 
knockout and overexpression of NFATc1. ALDH1A3 is one of the most important 
aldehyde metabolic enzyme in human cells. Metabolism reprogramming has been 
linked with the initiation, metastasis and recurrence of cancer. ALDH1A3 expression 
is associated with the development, progression, and prognosis of cancers. In addition, 
ALDH1A3 can act as a marker for cancer stem cells [155]. From the analysis of 
knockdown profiling, various metabolism related pathways are highly enriched in 
control cells compared with NFATc1-KD cells, which indicates that NFATc1 might 
regulate ALDH1A3 to influence the metabolism related pathways and leads to the 
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progress of malignancies. Compared with the healthy tissue group, ALDH1A3 was 
highly upregulated in PDAC group. However, upregulation of ALDH1A3 was not 
observed in Panc1 and Miapaca2 in comparison with HPDE. The enhanced 
expression of ALDH1A3 in PDAC tissues might be explained with probes in its 
promoter region were hypermethylated compared with the healthy tissues. Based on 
the methylation/unmethylation-motif of NFATc1, in silico FIMO analysis uncovered 
multiple NFATc1 methylated binding sites in the promoter region of ALDH1A3. 
According to the result of MSP, the candidate binding sites of NFATc1 were highly 
methylated in Panc1 and Miapaca2. In order to verify the effect of methylation on the 
expression of ALDH1A3, Panc1 and Miapaca2 were treated with the optimal 
concentration of 5-Azacitidine drug for 3 days followed with examination of expression 
level of ALDH1A3. Upon the treatment of 5-Aza, the expression of ALDH1A3 was 
downregulated in Panc1 and upregulated in Miapaca2. As known from previous 
experiments, NFATc1 was highly expressed in Panc1 compared to Miapaca2, which 
might explain why the expression of ALDH1A3 is downregulated in Panc1 upon 
demethylation but not in Miapaca2.  
 
Next, in order to verify that ALDH1A3 is a direct target of NFATc1, luciferase was 
performed accordingly. The result indicates that predicted promoter region of 
ALDH1A3 is active. Meanwhile, the promoter activity is positively associated with the 
expression level of NFATc1. When the promoter is methylated, the promoter is still 
showing the activity. Though the methylation isn’t increasing the promoter activity, the 
methylation doesn’t block the transcription. Together with the evidence that NFATc1 
preferentially bind with methylated motif, it’s concluded that ALDH1A3 is regulated by 
NFATc1 directly. After performing the luciferase assay, ChIP together with the 
demethylation treatment was performed to validate the methylated NFATc1 binding 
sites that were predicated in the promoter region of ALDH1A3. ChIP assays have 
successfully detected the binding signal of NFATc1 in Panc1, but not in Miapaca2, de-
methylated Panc1 and Miapaca2. These results indicate NFATc1 regulates the 
expression of ALDH1A3 directly in Panc1, and this regulation is methylation-
dependent. However, the failure of binding singal of NFATc1 in Miapaca2 might be 
resulted from the low expression of NFATc1 in this cell line. Additionally, systematic 
reliability has to be considered because high background signals in negative control 
of IgG via western blot of the lysates have been observed. ChIP is widely used to 
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dissect out the association of regulatory molecules to specific promoters and histone 
modifications in ex-vivo. While certain technical limitations exist in ChIP experiments 
[156], the reliability of ChIP result is highly dependent on the antibody quality. 
Moreover, it may cause false positive results due to fixation of transient proteins to 
chromatin, and inefficient chromatin recovery that might be acquired from target 
protein epitope disruption. To more precisely validate the binding of NFATc1 in the 
ALDH1A3 promoter region, luciferase assays of the predicted promoter region 
together with demethylation treatment are urgently needed. Since NFATc1 plays 
crucial roles in the progress of carcinogenesis, ChIP-BS-seq is needed to 
systematically discover more targets of NFATc1 to reveal the oncogenic mechanism 
associated with NFATc1.  
 
Taken together, ALDH1A3 is positively regulated by NFATc1, and it’s the first time to 
reveal the biological function of NFATc1 as a methyl-plus TF in PDAC. Moreover, 
ALDH1A3 is identified as a direct target of NFATc1 for the first time. In contrast to the 
traditional scenario that hypermethylation in the promoter region of a gene represses 
the expression of this gene, this study provides a new understanding that 
hypermethylation in the promoter region is not always blocking the transcription of the 
gene.  
 
How is the gene transcribed when the promoter is hypermethylated? In the 
examination of predicted primary structure of NAFT, NFATc1 is found to interact with 
CBP/p300 at the N-terminus transactivation domains (TAD) [157]. CBP/p300 are 
endowed with histone acetyltransferase (HAT) activity, which transfers an acetyl group 
from acetyl-CoA to form ε-N-acetyllysine and results in the activation of transcription 
and chromatin remodeling [158]. Although NFAT members share conserved domains, 
the highly variable TADs regions might have a critical role in NFAT function. One 
proposed model might be that NFATc1 firstly recognizes and stabilizes the methylated 
promoter as an anchor for the other co-activator. For example, CBP/p300 could 
recognize the N-terminus transactivation domains of NFATc1, acetylate the histone, 
remodel the histone, and co-activate the transcription. The working model of NFATc1 
is illustrated below. 
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NFATc1 binds to methylated cis-regulatory elements, followed by chromatin remodeling and 
transcription activation. 
 
In a summary, using a new experimental paradigm, this study has revealed that 
NFATc1 regulates the transcription of ALDH1A3, and thus exerts oncogenic role. 
Additionally, NFATc1 activates the transcription of ALDH1A3 via binding to its 
methylated regions. The work demonstrates such gene activation mechanism can 
mediate physiological functions in biologically relevant events. It’s demonstrated that 
mCpG has roles in regulating TFs binding, histone modifications and gene activations 
in a sequence-specific manner. Most importantly, this study has provided a new notion 
that TFs can act as a new class of DNA methylation effectors that drive gene 
transactivation in biological proc
 
 
 
 
 
 
Figure 5.1 Working model of NFATc1 
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Index: Primers and Oligonucleotides 
Primer name Sequence (5’-3’) Note 
M13_for GTAAAACGACGGCCAGT PCR primer 
M13_rev CAGGAAACAGCTATGAC PCR primer 
TF_for 
GAAATTAATACGACTCACTATAGGGAG
ACCACAACGGTTTCCCTCTAGAAATAA
TTTTGTTTAAGAAGGAGATATACATAT
GCATCATCATCATCATCATACTTTGTA
CAAAAAAGTTGGCATG 
PCR primer 
   
TF_rev 
CTGGAATTCGCCCTTTTATTACGTAGA
ATCGAGACCGAGGAGAGGGTTAGGG
ATAGGCTTACCTAATGCCAACTTTGTA
CAAGAAAGCTG 
PCR primer 
Twist1 promoter 
oligonucleotides 
AGTTGGGCGAGAGCTGCAGACTTGGA
GGCTCTTATACCTCCGTGCAGGCGGA
AAG 
PDI oligo 
NFATc1_sg1_for 
CACCGCCCGTATGAGCTTCGGATTG sgRNA 
sequence 
NFATc1_sg1_rev AAACCAATCCGAAGCTCATACGGGC sgRNA 
sequence 
NFATc1_sg2_for CACCGCGGAGGACACCCCATCGTGC sgRNA 
sequence 
NFATc1_sg2_rev AAACGCACGATGGGGTGTCCTCCGC sgRNA 
sequence 
NFATc1_sg3_for CACCGCTCCCGAAGACCGCAGCCGC sgRNA 
sequence 
NFATc1_sg3_rev AAACGCGGCTGCGGTCTTCGGGAGC sgRNA 
sequence 
Scramble_for CACCGATATCCGGAATTCGCGCGAT sgRNA 
sequence 
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Scramble_rev AAACATCGCGCGAATTCCGGATATC sgRNA 
sequence 
LKO.1 5' GACTATCATATGCTTACCG PCR primer 
Prisg1/2_for TCCATCTTAGAGAACTGGCC PCR primer 
Prisg1/2_rev TAACCACGACAGAGCATTC PCR primer 
Prisg3_for GAGACTCAGAGGCTCCGAAC PCR primer 
Prisg3_rev2 GGCAGAGGAGACACCTATTG PCR primer 
   
NFATc1-OE for 
TAGAGCTAGCGAATTCATGCCAAGCA
CCAGCTTTC 
PCR primer 
NFATc1-OE rev 
TCGCGGCCGCGGATCCTCAGAAAAAG
CACCCCACGCGC 
PCR primer 
MSP for ATGTATTAGAAGTCGTTTTCGTG PCR primer 
MSP rev CTCCTTTTACGATTTAAAAAACGC PCR primer 
ALDH1A3_ChIP for TCGCCAGTGTTAGCCAGCCGATAT PCR primer 
ALDH1A3_ChIP rev AAAGGTCTTGTGCTGTTATGGCCT PCR primer 
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List of abbreviations 
°C  Degrees Celsius  
ab antibody 
amp  ampicillin  
bp  Base pairs  
BSA  Bovine serum albumin  
cm  centimeter  
Ctrl Control 
C-terminus  Carboxy-terminus  
ddH2O  Double-distilled water  
DMSO  Dimethylsulfoxide  
DNA  Deoxyribonucleic acid  
dNTP Desoxyribonukleosidtriphosphate 
DTT  1,4-Dithiothreitol  
E. coli  Escherichia coli  
EDTA  Ethylenediaminetetraacetate  
e.g.  Exempli gratia  
ELISA  Enzyme-linked immunosorbent assay  
et al.  Et alii  
g  gramm  
h hour 
s second 
His Histidine  
HRP  Horse radish peroxidase  
i.e.  Id est  
Ig  Immunoglobulin  
INF-γ interferon-γ 
kD  kilo Dalton  
kV  kilovolt  
LB  Lysogeny broth  
LPS Lipopolysaccharide 
μl  microliter  
MFI  Median fluorescence intensity  
min  minute  
MIST Multiple spotting technique 
ml  milliliter  
mm  millimeter  
mM  millimolar  
NC Negative control 
nl  nanoliter  
nm  nanometer  
N-terminus  Amino-terminus  
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OD  
 
Optical density  
ORF Open reading frame 
PBS  Phosphate-buffered saline  
PBS-T  PBS-Tween  
PC Posive control 
PCR  Polymerase chain reaction  
PISA Protein in situ Arrays 
RBS Ribosome binding site 
RNA  Ribonucleic acid  
rpm  Rounds per minute  
TEMED  N,N,N’,N’-Tetramethylethylendiamin  
5mC 5-methylcytosine 
ALDH1A3 aldehyde dehydrogenase 1 family member A3 
ChIP chromatin immunoprecipitation 
CpG 5’-C-Phosphate-G-3’ 
CRISPR/Cas clustered regularly interspaced short palindromic 
repeats/CRISPR associated (protein) 
DNMT  DNA methyltransferases 
KRAS kirsten rat sarcoma viral oncogene homologue 
MBC methylated, bisulfite converted control DNA 
MBD methyl-CpG-binding domain 
MSP methylation-specific polymerase chain reaction 
NFAT nuclear factors of activated T-cells 
NFATc1 nuclear factor of activated T-cells 1 
PDAC pancreatic ductal adenocarcinoma 
TF transcription factor 
UBC unmethylated, bisulfite converted control DNA 
FDR false discovery rate 
CP chronic pancreatitis 
FC fold change 
GO gene ontology 
SD standard deviation 
scr scramble 
NES normalized enrichment score 
KO knockout 
KD knockdown 
OE overexpression 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis 
PDI Protein DNA interaction 
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